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The pharmaceutical industry is one of the most powerful and profitable industries in the 
world, valued at over a trillion dollars. People need and will always need medicine, but the 
enormous success of the pharmaceutical industry cannot simply be attributed to the inherent, 
enduring demand for their products. It is well documented that pharmaceutical companies 
often spend as much, or more money on marketing their existing products than on developing 
new ones. Developing new pharmaceuticals is extremely costly in terms of both time and 
money, so pharmaceutical companies often rely on marketing to create demand and drive 
profits. Pharmaceutical marketing spending has increased substantially over the years, and 
prescription drug consumption by Americans has followed the same trend. A large volume of 
literature has been written on the subject of pharmaceutical marketing, and there is an ongoing 
debate about the ethicality of the practice. This is because the marketing of pharmaceuticals 
differs greatly in many respects from the marketing of other consumer products. Unlike other 
markets, there are multiple agents involved on both the demand side and the supply side. 
Although patients are the end-users, physicians are the ultimate gatekeepers of prescription 
medications. Thus, pharmaceutical companies direct their marketing efforts towards both 
patients and physicians in the form of Direct to Consumer Advertising (DTCA) and Direct to 
Physician Promotion (DTPP). This thesis aims to provide an in-depth description of both DTCA 
and DTPP and the impact of these practices on physicians, patients, and prescription volume. In 
doing so, this thesis will examine the evidence on both sides of the debate surrounding 
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Whether we realize it or not, the minds of Americans are being manipulated and 
influenced by money-seeking institutions at each moment of every day. As humans, we possess 
a psychological tendency to continuously want and strive for more. Over the years, businesses 
have discovered how to increase their profits by catering to this psychological tendency, and as 
a result, we have come to live in a society where we are constantly being told we need 
something that we don’t have. This strategy is called advertising. The power of advertising is 
enormous and its presence is ubiquitous. Brands have made their way into every aspect of our 
lives to the point where we almost don’t notice them anymore. But when advertisements start 
to impact the prescription medication that we take and in turn, our physical health and well-
being, it is imperative that we do notice them and understand the incentives behind these 
advertising efforts. While advertising can present numerous potential benefits in terms of 
providing consumers with information and product alternatives, there are a number of ethical 
considerations that must be taken into account with regard to the marketing of prescription 
medication by the pharmaceutical industry. From 1997 to 2016, medical marketing spending 
increased from $17.7 billion to $29.9 billion and during that same time period, prescription 
drug use by Americans increased by 85% while the population rose only 21%.1,2 These 
advertisements are having their intended financial effect on the pharmaceutical industry’s 
bottom line, but what impact are they having on the health of the American population? While 
it is nearly impossible to measure the patient health implications of pharmaceutical marketing 
and that is not the focus of this paper, it is possible measure the impact in terms of the number 
of prescriptions filled and related expenditures.  
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 As a society, we hope that the pharmaceutical industry’s primary duty is to American 
healthcare consumers and that it is committed to the research, discovery, and development of 
new medicines to improve the lives of patients. Moreover, it is true that the pharmaceutical 
industry has introduced extraordinary health-care advances. The lives that the industry has 
saved and significantly improved through prescription medications are innumerable. But one 
must consider the other reality. Pharmaceutical companies are profit-making enterprises and 
like every other for-profit business, their duty to their shareholders to maximize profits also 
looms large. It is imperative that the pharmaceutical industry produces large profits in order to 
foster innovation and support the continuous development of life-saving drugs, but it is also 
crucial for society to consider the ethical concerns and potential conflicts of interest that arise 
from the use of advertising to maximize these profits. Before delving into pharmaceutical 
marketing practices, it is important to explain the prescription drug development process as a 
whole in order to more clearly understand the role of marketing in pharmaceutical success. Part 
I of this report will describe the process of bringing a new pharmaceutical product to market, 
examine the role of marketing in that process, and analyze pharmaceutical marketing 
expenditures over the years. Part II of this report will look specifically at the pharmaceutical 
practice of marketing to physicians to examine trends in spending, describe the different 
marketing methods used and analyze the impacts of the different practices. Part III of this 
report will focus the pharmaceutical practice of marketing to directly to consumers to examine 
trends in spending, describe the types of advertisements and the nature of the promotional 
content, and discuss the pros and cons of the practice. Lastly, Part IV of this report will examine 
the impact of using DTPP and DTCA in combination to market a pharmaceutical product.  
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Part I: The Bigger Picture 
Background: Bringing a New Drug to Market 
The process of developing a pharmaceutical medication is extraordinarily expensive and 
time consuming. According to a study published by the Tufts Center for the Study of Drug 
Development in 2016, the cost of bringing one single new drug to market is $2.6 billion.3 
Moreover, the likelihood of a drug candidate making it to the market is extremely low. 
According to The Truth About Drug Companies, the number is close to one in five thousand.4 In 
recent years, many individuals have accused the pharmaceutical industry of investing more 
resources into their marketing efforts than into the research and development (R&D) process. 
Many feel that the pharmaceutical industry should allocate the majority of their budget to 
researching and developing new life-saving medicines, rather than marketing the ones they 
already have. The pharmaceutical industry argues that marketing is necessary for profit, and 
profit is necessary to foster innovation within the R&D sector. While this report primarily 
focuses on pharmaceutical marketing, it is important to understand the drug development 
process as a whole in order to fully understand the role of marketing in the larger success of a 
pharmaceutical product. With that being said, this report will briefly describe each of the costly 
phases involved in the creation of a new drug which are illustrated in Figure 1 below. 






The process begins with the Discovery phase, which is comprised of research and 
development (R&D) activities. The research aspect of this phase is usually the most time-
consuming, and most difficult portion of the entire process, as those involved must develop an 
intense understanding of the disease in question in order to have any hope of developing a 
drug that will safely and effectively interfere with the chain of events that is causing the 
condition. The majority of the time, this research is carried out at universities or government 
research laboratories. In the United States, most research efforts are supported by the National 
Institute of Health (NIH).4 Once research is completed, and the individuals involved have a 
thorough understanding of the disease and potential ways to address it, the development 
process begins.  
In the development phase, scientists begin searching for or constructing a molecule that 
could effectively and safely treat the disease. Pharmaceutical companies usually become more 
heavily involved at this point if the research was conducted by outside sources like a university 
or the government. Choosing the therapeutic area for investment of time and resources 
depends on number of factors such as: medical need, technical feasibility, research and 
development costs and commercial considerations such as market place competition and 
potential market share.5 The pharmaceutical companies research and development budget is 
limited, so only those projects with the highest potential can be selected. Once a project has 
been selected, the development process consists of two main stages—the pre-clinical phase 
and the clinical phase. 
During the pre-clinical phase, a number of potential drug candidates, which are small 
molecules that have strong therapeutic potential, are identified. Drug candidates are either 
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selected from extensive “libraries” kept by pharmaceutical companies, synthesized, or 
extracted from animal, plant, or mineral sources.4 The chosen candidates then undergo 
laboratory and animal testing in order to answer basic questions about the drug safety. 
According to The Truth About Drug Companies, only one in one thousand candidates survive the 
preclinical testing phase.4 It is also during this phase that decisions about whether to patent the 
compound or chemical series are made. This is because it becomes very difficult to keep 
information about the potential product a secret after this point. The life of a patent is typically 
around 25 years, and unfortunately it typically takes 10-15 years to develop the drug.5 Thus, 
once the drug is on the market, there could only be about 10 years remaining to sell the drug 
and make up for the high development costs.  Thus, pharmaceutical companies are very eager 
to complete the trials and obtain FDA approval so that they can begin marketing the new drug. 
The clinical stage of developing a pharmaceutical product is divided into three phases, 
as illustrated in the diagram above. All three of these phases are regulated by the FDA. Before 
the clinical trials can begin, pharmaceutical companies must file an investigational new drug 
application (INDA) with the agency.4 The evidence presented in the three phases is used in the 
FDA’s decision-making process when determining a drug’s safety and efficacy. Beginning in 
Phase I and continuing through Phase III, the product is administered to human volunteers. 
During Phase I, the drug is given to a small number of usually normal volunteers (humans that 
do not have the disease). The purpose of Phase I is to “evaluate the safety, tolerability, 
pharmacodynamic (effect of the drug on the body [e.g., effect on heart rate, blood pressure, 
electrocardiogram (ECG), etc.]) and pharmacokinetic (effect of the body on the drug [i.e., 
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absorption, distribution, metabolism and excretion]) effects of the tested drug.”5 In simple 
terms, they evaluate the drug’s metabolism and side effects and establish safe dosage levels.  
During Phase II, the drug is tested for efficacy and safety on the target population (the 
people with the condition that the drug is meant to treat). This phase involves as many as a few 
hundred volunteers who are given the drug at various doses. As with any other scientific study, 
the effects on the patients given the drug are usually compared with a placebo group (group of 
volunteers who do not receive the drug). Phase II is a key stage of development during which a 
detailed analysis of the drug and the market are conducted. This analysis includes: “drug 
efficacy relative to the competitors, safety profile, probability of technical and regulatory 
success, remaining patent life of the drug, cost of goods to produce the drug, potential market 
share and pricing and reimbursement.”5 Subsequently, the drug is compared to all of the other 
candidates in the portfolio before it is selected to move onto Phase III. The results of this phase 
are discussed with the FDA and regulatory agencies as well.  
During Phase III, the drug is tested on several thousand patients in order to build an 
adequate database to assess the efficacy and safety profile and enable accurate drug labeling. 
This phase will “confirm the clinical doses, frequency and timing of administration for 
approval.”5 Furthermore, “phase III trials are primarily designed and powered to test the 
hypothesis of efficacy but at the same time, adverse events are collected to assess benefit-risk 
potential of the drug.”5 A drug successfully making it through all three phases of clinical testing 
is rare. According to The Truth about Drug Companies, only one in five drugs survive clinical 
testing and make it to market.4 Figure 2 illustrates the number of drugs and their location in the 
development pipeline during 2018 and 2019.  
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If a drug is successful in clearing the phases of clinical testing, the drug moves on to the 
regulatory submission and approval stage, during which the pharmaceutical company compiles 
all of the results from the clinical trials, along with other supporting evidence, and submits it to 
the regulatory agency (the FDA). The FDA reviews new drug applications with the help of 
eighteen advisory committees consisting of outside experts.4 In the United States, a routine 
New Drug Application (NDA) can take up to 15 months for review.5 Once a drug has been 
approved to go to market, pharmaceutical “companies are permitted to promote the product 
only for the uses and at the doses for which they were approved, although once they are on the 
market, doctors may prescribe them for any use and at any dose they deem appropriate.”4 
Many pharmaceutical industry representatives have long been critical of the lengthy process of 
getting a new drug approved by the FDA, claiming that they put “bureaucratic obstacles in the 
way of getting ‘lifesaving drugs’ to the market.”4 While 15 months may seem long when 
considering patients’ lives (as well as the dwindling patent life), the time for FDA approval only 
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accounts for a small fraction of the total development time. Additionally, the review by the FDA 
is a vital step in the development process that should not be rushed. It is imperative that an 
impartial agency carefully reviews the scientific data about a potential new drug in order to 
protect the welfare of Americans.  
As one can see, the process of bringing a new drug to market is extremely complex and 
costly in a number of ways. This cost is even higher when considering the cost of failed 
prospective drugs. The failure rate of pharmaceutical products is referred to as the “attrition 
rate,” and it is remarkably high.5 As mentioned previously, it is estimated that only one in five 
thousand initial drug candidates survive all phases of development and enter the market.4 
Furthermore, Tamimi explains that “increasing costs combined with the high attrition rate are 
forcing pharmaceutical companies to reduce investment in research and development, focusing 
on a more limited product portfolio.”5 Because developing a drug is so incredibly risky and 
costly, it is imperative that the products they are able to successfully develop perform well and 
produce large profits to drive innovation. Thus, pharmaceutical companies invest an enormous 
amount in marketing those products that do successfully make it to market. According to 
Ezekiel Emanuel, “of the 10 largest pharmaceutical companies, only one spends more on 
research than on marketing its products.” Table 1 illustrates this statement, comparing R&D 





Table 1. Comparison of Research and Development Spending versus Sales and 










While this chart indicates that 9 out of the top 10 pharmaceutical companies spent more on 
sales and marketing than on R&D during 2014, it must be noted that there are no definitive 
reports that establish the industry’s cost structure. The ambiguity surrounding the allocation of 
pharmaceutical expenditures is at the heart of the current debate about whether the industry is 
truly focused on research and developing new drugs or on driving profits through marketing 
efforts.8 While this report will not delve into this argument about whether pharmaceutical 
companies should be allocating more of their budgets to research and development, it is 
important to understand the complexity of the drug development process in order to clearly 
see why marketing plays such an enormous role in pharmaceutical success.  The remainder of 
this report will focus on pharmaceutical marketing—examining spending, forms of marketing, 
 14 
and the impact of these practices on physicians, patients, and ultimately pharmaceutical 
industry profit.   
Pharmaceutical Marketing  
Marketing plays a massive role in the success of prescription medication sales as shown 
by the sheer amount of resources the pharmaceutical industry has invested and continues to 
invest in their marketing efforts. Figure 3 illustrates the increase in medical marketing spending 
by pharmaceutical companies from 1997 to 2016 and shows that marketing of prescription 
drugs accounts for a large majority of those expenditures. 









As shown, medical marketing spending expanded substantially during this time period, from 
$17.7 in 1997 to $29.9 billion in 2016.1 This figure has continued to increase into 2019 and 
pharmaceutical marketing expenditures have reached an all-time high. According to a 
QuintilesIMS Institute Study2, these promotional efforts have had their intended effect of 
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increasing prescription medication use, as the United States is the most highly medicated 
country in the world.9 









As the total number of prescriptions filled by all Americans increased from 2.42 billion in 1997 
to 4.47 billion in 2016 (Figure 4) and America’s expenditures on prescription drug increased by 
50% from 2010 to 2018 (reaching $535 billion), it is clear that pharmaceutical marketing is 
effective.2 But what makes it so effective? This report will thoroughly examine the 
pharmaceutical industry’s marketing methodology to answer this question, as well as the 
question of whether ethical lines are being crossed to achieve this effectiveness.  
The marketing of pharmaceuticals differs greatly in many respects from the marketing 
of other consumer products. Unlike other markets, there are multiple agents involved on both 
the demand side and the supply side. Although patients are the end-users, physicians are the 
ultimate decision makers and gatekeepers of pharmaceuticals. Thus, pharmaceutical companies 
direct their marketing efforts towards both patients and physicians in the form of Direct to 
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Consumer Advertising (DTCA) and Direct to Physician Promotion (DTPP). Pharmaceutical 
companies have employed DTPP since the beginning of pharmaceutical manufacturing. Because 
physicians are the agents that ultimately enable prescription medication sales, gaining their 
favor and approval is imperative to meeting pharmaceutical sales goals. Thus, the majority of 
pharmaceutical marketing budgets have long been allocated to DTPP. Direct to Consumer 
Advertising has also been employed for decades, but it appears that pharmaceutical companies 
have significantly increased their DTCA efforts in recent years. The pairing of DTCA with DTPP is 
a powerful one-two marketing punch. Pharmaceutical companies encourage consumers to see 
physicians about prescription drugs, and furthermore, they encourage physicians to prescribe 
these drugs. This report examines these two practices individually in-depth, as well as the 
effects of combining the two.   
Part II: Direct to Physician Promotion 
One of the most widely held concerns about pharmaceutical marketing is the practice of 
targeting physicians, also known as Direct to Physician Promotion (DTPP). Physicians are 
expected to be objective, unbiased parties who make decisions about the treatment of their 
patients using evidence-based medicine and other factors such as social drivers of health (e.g., 
the patients’ health literacy level, social support system, beliefs about health and treatments, 
insurance status, and others factors). Their patients place an extremely high level of trust in 
them, and rely on them to provide the best possible treatment to their knowledge. Over the 
years, there has been an enormous volume of literature published on this subject. While people 
hold a variety of opinions about the practice of DTPP, there is an overwhelming consensus that 
an inherent conflict of interest arises when physicians are put in situations where they may be 
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tempted to deviate from their professional obligations for financial or other personal gains. The 
pharmaceutical industry, physicians, and society as a whole seem to be acutely aware of the 
existence of this issue, yet this practice continues to be an integral aspect of pharmaceutical 
promotion. After conducting a comprehensive literature search, it appears that the majority of 
studies on DTPP were conducted prior to 2015. The nature of DTPP practices may have evolved 
in more recent years, but it is still heavily utilized, and the information presented in many of the 
studies continues to be relevant. Throughout this report, I will cite relevant literature to 
examine a number of DTPP practices and the impact they may have on physicians and on their 
subsequent prescribing behaviors.  
The main reason that DTPP has continued to persist in spite of its many critics is that it is 
highly effective, and in turn, profitable. Pharmaceutical companies rely heavily on physician 
acceptance and support of their drugs. While patients are the ultimate consumers of 
medications, physicians are the gatekeepers. Thus, the pharmaceutical industry invests a 
massive amount of resources into DTPP, more than any other area of promotion. The 
pharmaceutical industry has practiced DTPP since the origin of the industry, but their efforts 
have substantially increased in recent years. From 1997 to 2016, marketing to medical 
professionals increased from $15.6 billion to $20.3 billion.1 Figure 5, taken from Medical 
Marketing in the United States, depicts spending patterns for specific types of DTPP during this 













Given the nature of DTPP, and the variety of activities it entails (both direct and indirect) the 
estimates of the amount spent on the promotional practice vary. According to an article 
published in The PEW Charitable Trusts, the pharmaceutical industry spent over $27 billion on 
promoting pharmaceuticals in 2012 and $24 billion of that was dedicated to marketing to 
physicians.10 DTPP promotion involves a number of different practices which will be covered in 
more detail later in this report. Figure 6 depicts the resources allocated to each of these 
different DTPP areas as well as DTCA in 2012.  







The bulk of the DTPP budget is dedicated to detailing (personal selling through sales 
representatives) and sampling (provision of drugs to physicians at no cost to them). According 
to Connors, pharmaceutical companies spent around $25,000 annually per physician on 
marketing efforts in 2009.9 This number increased substantially from 2000, when about $8,000 
to $13,000 was spent per physician.11 It is clear from the size of the investment just how 
valuable DTPP is to pharmaceutical sales success. According to Schwartz and Woloshin, for 
every dollar the industry invests in DTPP for new branded drugs, it returns ten.1 But why is 
DTPP so effective? The remainder of this report will provide a detailed examination of specific 
DTPP practices and their impact, and additionally it will consider whether these practices cross 
an ethical line to produce such success.  
 The marketing efforts directed at physicians are comprised of a number of activities, 
some of which are directly labeled and identified as marketing efforts, while others use more 
indirect and discrete tactics used to gain the favor of physicians. Some of the most notable 
DTPP practices include: detailing, sampling, educational and promotional meetings, continuing 
medical education (CME), medical journal and web advertisements, promotional mailings, and 
grants to health advocacy organizations. While some doctors may be skeptical of interacting 
with pharmaceutical industry representatives, the overwhelming majority of them do. 
According to an article from The New England Journal of Medicine, 94% of physicians had a 
relationship with the industry in 2007.12 So, despite the fact that many physicians deny the 
potential influence of pharmaceutical promotion on their behavior, it is important to analyze 




 The Food and Drug Administration (FDA) is the regulatory agency that is responsible for 
overseeing and regulating DTPP (as well as the pharmaceutical industry as a whole). In the 
United States, the Federal Food, Drug, and Cosmetic Act (FDCA) and Title 21 of the Code of 
Federal Regulations Part 202 are the two primary pieces of legislation that govern prescription 
drug advertising and promotion both to physicians and consumers.13 The FDCA was passed in 
1938, and requires that pharmaceutical companies demonstrate drug safety prior to market 
sale.9 The Code of Federal Regulations contains FDA rules that prohibit pharmaceutical 
companies from publishing false and misleading advertisements.9 Over the years, there has 
been growing concern about the extent to which the pharmaceutical industry interacts with 
physicians and the conflicts of interests that arise from these interactions. As a result, the 
Physician Payments Sunshine Act was passed in 2010, and it “requires medical product 
manufacturers to disclose to the Centers for Medicare and Medicaid Services (CMS) any 
payments or other transfers of value made to physicians or teaching hospitals.”14 Additionally, 
the “National Institutes of Health requires all grantees to disclose significant financial 
relationships with manufacturers.”14 In addition to regulation at the federal level, at least five 
states and the District of Colombia have passed laws “requiring that manufacturers of drugs, 
devices, biologicals, and medical supplies report various details of their financial relationships 
with clinicians.”14 In addition to regulation by the government, various groups have published a 
variety of voluntary guidelines in an attempt to mitigate the potential issues that arise from 
DTPP. These groups include “the Office of the Inspector General, AMA, the American Board of 
Internal Medicine Foundation, PhRMA, and the Advanced Medical Technology Association 
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(Advamed).”9 All of these guidelines address specific aspects of DTPP and set standards for how 
the pharmaceutical industry should interact with physicians in order to protect the interest of 
patients. It is important to note that the guidelines published by these groups are voluntary and 
aspirational, meaning that pharmaceutical companies cannot be punished for straying from the 
voluntary rules set forth. Thus, the arguably relaxed regulation of pharmaceutical marketing has 
allowed the pharmaceutical industry to promote their products to physicians in a number of 
effective but potentially questionable ways.  
Detailing 
By far, the largest portion of DTPP expenditures are dedicated to the practice of 
detailing, a marketing technique in which pharmaceutical sales representatives (PSRs) visit 
physicians’ offices in order to educate physicians about new pharmaceutical products in the 
hope that they will prescribe them more frequently in the future. In 2016, the pharmaceutical 
industry spent $5.6 billion on the practice of prescriber detailing.1 According to a 2007 article 
from PLOS Medicine, the number of pharmaceutical sales representatives in America increased 
from 38,000 in 1995 to 100,000 in 2005.15 PharmaOpportunties reported that number of 
pharmaceutical sales representatives world-wide will increase by 16.4 percent between 2012 
and 2022, growing to 400,000.16 The authors of the PLOS Medicine article note that there is 
about one PSR for every six physicians. They go further to argue that the actual ratio is close to 
one PSR per 2.5 targeted doctors because not all physicians practice and pharmaceutical 
companies do not detail all physicians (the lower-prescribing physicians are not prioritized). 15 
According to 2013 estimates, a PSR typically details about 5-10 physicians per day.17 
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These numbers include physicians at a variety of seniority levels, as pharmaceutical 
companies employ detailing to target physicians throughout various stages of their careers, 
beginning as early as medical school and residency. Connors cites a 2009 study that revealed 
that “56% of medical students had three or more conversations with pharmaceutical 
representatives during medical school.”9 According to a 2017 systematic review conducted by 
Fickweiler, Fickweiler, and Urbach, “attending physicians and physician specialists had more 
PSR interactions and received higher numbers of medical samples and promotional material 
than residents,” but the authors note that most residents have at least one interaction with a 
pharmaceutical industry representative per month.18 A potentially troubling finding of this 
article noted that residents interacted with PSRs and received samples far more frequently at 
the beginning of their residencies.18 Connors explains that these findings may be a cause for 
concern as “medical students and residents are particularly susceptible to marketing tactics, as 
these individuals are in a submissive position—often being overworked, without experience, or 
practical knowledge of ethics rules, and with respect to residents, severely underpaid.”9 Along 
these lines, one must consider that medical students and residents may be more vulnerable to 
these marketing tactics as they may not yet be able to decipher between promotional material 
and scientific facts and recognize the potential influence on their behavior.11  
Regardless, PSRs play a critical role in DTPP and are highly compensated for their efforts. 
The average PSR in 2018 earned a salary of about $43,098-$73,178 and depending on their 
level of success in convincing physicians to prescribe their products, a substantial bonus.16 For 
example, the base salary at one of the top pharmaceutical companies, Pfizer, was $82,374 in 
2018, but their total compensation was about $99,298.16 The practice of detailing is utilized 
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most heavily in the early stages of a pharmaceutical product’s life cycle (6-14 months following 
the drug’s launch).17 According to a 2014 paper from the National Bureau of Economic 
Research, this is because “uncertainty regarding the efficacy of the drug and its attributes 
including the safety profile” tend to be highest during the early stages. 17 Thus, in the beginning, 
the role of the PSR is for the most part educational and informative. Because the role of the PSR 
is to educate physicians about new pharmaceuticals, one might assume that this interaction 
would diminish in the later stages of a pharmaceutical’s life cycle, as there should be no new 
information to convey. But, both this article and an article from the Yale Journal of Health 
Policy, Law, and Ethics found that interactions between physicians and PSRs do continue into 
the later stages of a pharmaceutical’s life cycle.17,19 The authors of both of these articles came 
to similar conclusions in developing an explanation for this occurrence, stating that DTPP 
evolves from an informative role during the early stages into a more persuasive role during the 
subsequent stages.17,19 Manchanda and Honka state that detailing during the later stages 
provides a “reminder effect” and additionally, the “constant interaction builds a stock of 
goodwill between a detailer (or the firm) and the physician, translating into positive physician 
prescription behavior.”19 This pattern reflects the well-known, but infrequently acknowledged, 
reality that the purpose of detailing is not only to educate, but also to build long-lasting, 
reciprocal relationships with physicians.  
In the 2007 article from PLOS Medicine, co-authored by a former PSR for Eli Lilly named 
Shahram Ahari, the authors state that “drug reps are selected for their presentability and 
outgoing natures, and are trained to be observant, personable, and helpful.”15 What makes 
detailing so effective is how personal the practice is. PSRs don’t just simply distribute 
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information in a transactional sense. As previously mentioned, PSRs attempt to befriend 
physicians and build relationships. The job of a pharmaceutical sales representative goes far 
beyond simply distributing samples of and information about new pharmaceutical products. 
The same former PSR, Shahram Ahari, published an article in the Washington Post revealing 
exactly what his job entailed.  
“I took doctors out to so many fancy Manhattan restaurants that the maitre d's greeted 
me by name. The company hosted them at catered "speaking programs" and gave away 
tickets to baseball games and Broadway musicals. We even sent doctors and their 
families to sponsored academic conferences at tony resorts in Florida and California. 
During the day, if doctors didn't have time to see me, I chatted up their receptionists, 
plying them with food and gifts (stress balls, umbrellas, clocks) and asking, breezily, 
which medications their bosses preferred prescribing, and why.” 15 
Ahari makes note that his description of the industry may differ from the current situation, as 
he was a PSR in 2000, prior to the regulatory crackdown of 2009, after which the Sunshine Act 
was passed and pharmaceutical companies adopted a voluntary code of conduct that among 
other restrictions, permitted only "modest, occasional meals" in "appropriate circumstances," 
facilitating "the exchange of medical and scientific information."20 Yet, many feel that the new 
regulatory requirements did little to eliminate the issues.   
Still today, the way that PSRs approach each physician is unique and carefully planned. 
In discussing his job as a PSR in the PLOS Medicine article, Shahram Ahari stated, “It's my job to 
figure out what a physician's price is. For some it's dinner at the finest restaurants, for others 
it's enough convincing data to let them prescribe confidently and for others it's my attention 
 25 
and friendship...but at the most basic level, everything is for sale and everything is an 
exchange.”15 PSRs expend a substantial amount of time and energy understanding physicians 
and their preferences in order to build relationships and in turn, meet their sales quotas. These 
long-lasting relationships, among other factors, are what create consistent and frequent 
prescribing, and in turn steady profits. 
While the pharmaceutical industry may claim that PSRs visit physicians in order to 
distribute information and educate physicians, they also visit to gather information. The PLOS 
Medicine article reveals that PSRs “are also trained to assess physicians' personalities, practice 
styles, and preferences, and to relay this information back to the company.”15 Pharmaceutical 
companies rely heavily on the information collected by PSRs. The information collected by PSRs 
is stored in a database and utilized in developing future marketing strategies. In addition to 
collecting personal information about physicians to enhance PSR strategies, pharmaceutical 
companies also gather information on their prescribing behaviors through a practice known as 
data mining.21 Pharmaceutical companies get access to this information by purchasing 
prescribing data from prescription drug intermediary (PDI) companies, information distribution 
companies, or health information organization such as IMS Health, Dendrite, Verispan, and 
Wolters Kluwer.15,21 These companies purchase prescription records from pharmacies, many of 
which do sell these records. Patient and physician names are not included, but the data does 
sometimes contain physicians’ state license numbers, Drug Enforcement Administration 
numbers, or a pharmacy-specific identifiers.15 According to an article from The New England 
Journal of Medicine, these companies are able to link these records to physician information 
that they purchase from the American Medical Association (AMA).21 The AMA maintains the 
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Physician Masterfile, which is “a database containing demographic information on all US 
physicians (living or dead, member or non-member, licensed or non-licensed).” 15 
 Pharmaceutical companies are the primary customers for prescribing data.21 Companies 
use this information to identify physicians known as high decile prescribers and additionally to 
track the impacts of their promotion efforts. Specifically, the PSRs use this prescribing data “to 
see how many of a physician's patients receive specific drugs, how many prescriptions the 
physician writes for targeted and competing drugs, and how a physician's prescribing habits 
change over time.”15 There has been increasing concern about pharmaceutical companies’ 
ability to utilize physician-identifiable prescribing data. This concern prompted at least 25 states 
to consider legislation that would restrict pharmaceutical access to such data.21 Vermont, New 
Hampshire, and Maine attempted to pass such laws but immediately faced resistance from 
prescription drug intermediary companies and a trade association of pharmaceutical 
manufacturers.21 According to The New England Journal of Medicine article, “One of these 
challenges reached the nation's highest court this year (2011), and on June 23, the Supreme 
Court struck down Vermont's statute by a vote of 6 to 3, holding that in practical effect, the law 
unconstitutionally restricted the speech of pharmaceutical companies and PDIs on the basis of 
the viewpoint it expressed.”21 Given the court’s decision, pharmaceutical companies still utilize 
this data today. With this information, pharmaceutical companies can identify those physicians 
who are the most receptive to their marketing tactics and personalize their strategies in an 
attempt to influence their prescribing behavior. By identifying these high decile prescribers, 
pharmaceutical companies are able to allocate their promotional resources more efficiently and 
in turn, produce a higher Return on Investment (ROI). One must consider the idea that if 
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detailing was truly a practice that served to educate physicians, then pharmaceutical companies 
would target all physicians, not just those who frequently prescribe their pharmaceuticals. 
Detailing: Impacts 
Pharmaceutical companies have continued to dedicate extensive resources to the 
practice of detailing because it is an extremely effective way to drive prescriptions sales. 
Multiple studies have documented that physicians’ interactions with PSRs have a substantial 
effect on their prescription behavior. The pharmaceutical industry specifically acknowledges 
that detailing likely has an impact on physician prescribing behavior, but the industry believes it 
serves several beneficial purposes. They contend that “such marketing is welfare-enhancing 
and remains an important source of physician learning.”17 According to a JAMA article, these 
purposes include “introduction of physicians to new medications, encouragement to use the 
most effective medications, improvement of the likelihood that they will follow good practice 
guidelines, and access to medications for low-income patients.”22 Additionally, an article from 
the National Bureau of Economic Resources notes that the industry feels that “detailers provide 
valuable information concerning the drug’s indications and counterindications, which in turn 
allows physicians to make better-informed choices.”17 Whether the impact of detailing on 
physician behavior is beneficial or detrimental is a subject of debate, but this report will 
describe both the positive and negative impacts found in multiple studies.  
Manchanda and Honka conducted an integrative review of literature in 2005 to reveal 
the effects of DTPP and published their findings in the Yale Journal of Health Policy, Law, and 
Ethics. The authors found that physicians rely on detailing as an important source of 
information, as it is inexpensive and convenient.19 According to a study that surveyed Iowa 
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physicians about the frequency with which they use certain sources of drug information, PSRs 
were second after pharmaceutical text books. 19 While physicians admit to frequently using the 
pharmaceutical industry as a source of information, the authors describe a 1994 study that 
revealed that only 20% of physicians “believed in the accuracy and objectivity of presented 
information, while 44% did not.” 19 While it appears physicians do not place a high level of trust 
in the quality of the presented information, the study still indicated that the practice affects 
physician behavior in a “positive and significant manner.”19 Approximately 56% of doctors in 
the previously mentioned study admitted that PSRs could “influence formulary decisions if 
efficacy, toxicity, and cost were the same, while 28% disagreed with this statement.” 19 
Moreover, according to a 1990 study that surveyed doctors at teaching hospitals, “25% of 
faculty and 32% of residents reported having changed their practices at least once in the 
preceding year based on contact with a detailer.”19 Another 1994 study surveyed 262 
practitioners and found that 70% admitted that detailing affected their prescribing habits. 19 
This same study also found a strong positive association between the number of PSR visits and 
the number of prescriptions per week.19 While the studies described in this integrative review 
are significantly dated, they are worth noting because many of the findings have remained 
constant in more recent literature.   
A 2010 systematic review published in PLOS Medicine revealed additional relevant 
findings.23 These authors examined multiple studies to reveal how the exposure to information 
from pharmaceutical companies affects the quality, quantity, and cost of physicians’ 
prescribing. Overall, the study found that “with rare exceptions, studies of exposure to 
information provided directly by pharmaceutical companies have found associations with 
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higher prescribing frequency, higher costs, or lower prescribing quality or have not found 
significant associations.”23 Specifically, this review examined 29 studies about the effects of 
sales representative visits and found that 17 of the studies found an association with increased 
prescribing of the promoted drug. 23 Of the 11 remaining studies, six of them had mixed 
results—"finding a significant association with more frequent prescribing for some measures 
but no significant association for others.” 23 The other five did not detect any significant 
relationship between sales representative visits and prescription volume. 23 These studies also 
looked at specific characteristics of the PSR visits and their corresponding impacts. They found 
that longer PSR visits were more likely to be associated with increased prescribing. 23 
Additionally, they found that “an association with more frequent prescribing was more likely 
when pharmaceutical sales representatives visited groups of physicians, when physicians had 
lower baseline prescribing of the promoted drug, and when physicians had larger prescribing 
volumes overall.” 23 In terms of prescribing quality, the authors discuss a study that revealed 
that primary care doctors who saw more PSRs and used the pharmaceutical industry as a 
source of information prescribed a wider range of drugs. They note that the authors of this 
study suggest that “this was a sign of lower prescribing quality in the context of 
recommendations that primary care providers use a limited list of drugs they know well.”23 
Most doctors still deny that interacting with PSRs and the pharmaceutical industry in general 
affects their behavior, but from these reviews and the numerous studies cited, the existence of 





The second largest portion of DTPP expenditure is allocated to the practice of providing 
samples, which is essentially medicine given to physicians at no cost to them. This practice is 
closely related to detailing, as pharmaceutical companies rely on pharmaceutical sales 
representatives (PSRs) to deliver these samples directly to physicians. According to Medical 
Marketing in the United States, spending on the distribution of free samples increased from 
$8.9 billion in 1997 to $13.5 billion in 2016.1 At the surface, the purpose of sampling is to allow 
physicians and patients to “try” the new product in order to evaluate tolerance and preference 
before they decide to spend money on the costly product. According to a PLOS Medicine article, 
the underlying pharmaceutical objective of supplying samples “is to gain entry into doctors' 
offices, and to habituate physicians to prescribing targeted drugs.” 15 The pharmaceutical 
industry claims that sampling has a number of positive impacts. Chimonas and Kassier note 
that, “in two separate news releases within the past year by the Pharmaceutical Research and 
Manufacturers of America (PhRMA) […] a senior vice president claimed that free samples 
improve patient care, foster appropriate medication use, and help millions of financially 
struggling patients.”24  
It is clearly documented that physicians appreciate samples, which allow them to “start 
therapy immediately, test tolerance to a new drug, or reduce the total cost of a prescription.” 15 
Even those doctors who are skeptical about detailing and limit their interactions with PSRs 
usually want and accept free samples that are provided.15 Patients also appreciate the free 
samples, which eliminate the need to stop at a pharmacy on the way home when they may not 
be feeling well or have other considerations, such as children in the car. Additionally, Big 
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Pharma and many physicians assert that the practice of sampling benefits poor patients by 
reducing their prescription costs. However, many studies have found that this assertation is not 
accurate, as “poor patients are less likely than wealthy patients to receive drug samples, and 
free drug samples often transition to paid prescriptions that can drive significant extra costs per 
patient per month.”25 A nationally representative survey of the United States conducted in 
2008 revealed that fewer than one-third of patients who received samples were considered 
low-income (less than 200% of the poverty line).24 Kessel additionally analyzed the truth of this 
claim in a 2014 Nature Biotechnology article. He revealed that research has indicated that the 
majority of free samples are dispensed to insured patients whose prescriptions are covered, 
and that those patients who do receive samples ultimately end up paying higher prescription 
costs because “they are then prescribed the sampled drug rather than a less-expensive generic 
alternative.”26 Additionally, pharmaceutical companies don’t provide samples of all of their 
products. Studies have revealed that the pharmaceutical products selected for sampling tend to 
be the more expensive, name-brand drugs rather than the less expensive, generic alternatives. 
It is important to note that the distribution of samples to physicians is largely unregulated 
nationally, as a physician’s receipt of samples are exempt from Sunshine Act Reporting.25 Thus, 
it is left to physicians to decide whether the receipt of such gifts has an unethical impact on 
their behavior. It is clear that the promotional tactic of sampling provides a high ROI by gaining 
the loyalty of physicians to both the pharmaceutical manufacturer and their products, and this 





The provision of free samples may have a number of positive impacts in terms of 
creating convenience for patients and allowing physicians to test their satisfaction with new 
pharmaceutical products. That being said, multiple studies have revealed that sampling also has 
a number of negative impacts. While pharmaceutical companies would never recognize 
samples as a form of “gift,” in reality, they are. According to the 2017 study conducted by 
Fickweiler, Fickweiler, and Urbach, the most common “gift” that physicians receive are 
samples.18 In his 2014 Clinical and Translational Gastroenterology article, Lahey discusses the 
idea that while sampling may not technically be considered a gift from the pharmaceutical 
companies’ perspective, it may subconsciously feel like one to physicians and create a sense of 
obligation.25 The author cites a 2003 study that reveals evidence indicating that gifts of any 
value strongly influence the recipient’s behavior.25 Upon the receipt of samples, physicians are 
more likely to show loyalty to both the PSRs and the drugs that they represent.25 Multiple 
studies have shown that the distribution of samples results in substantial increases in new 
prescriptions for the promoted drug which translates to higher sales volumes and profits for the 
pharmaceutical industry.11,24,25  
Wazana conducted an analysis of 29 studies about physician interaction with the 
pharmaceutical industry and found that the acceptance of free samples by physicians was 
associated with “awareness, preference and rapid prescription of a new drug, and a positive 
attitude toward the pharmaceutical representative.”11 Although it may increase awareness, 
sampling may tempt physicians to cross an ethical line and stray from their unbiased, expert 
medical opinion. The 2014 article written by Lahey in Clinical and Translational 
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Gastroenterology reveals that physicians are more likely to prescribe medications given to them 
as free samples “even if that choice is irrational or not otherwise their first choice.”25 In a 2009 
article from PLOS Medicine, Chimonas and Kassier note a study that revealed that “residents 
with access to samples were more likely than their counterparts without samples to prescribe 
heavily advertised products and less likely to suggest an over-the-counter alternative.”24  
Chimonas and Kassier discuss another issue with sampling pertaining to the bypassing of 
drug interaction checks and counseling by pharmacists. “In drugstores, pharmacists often 
identify potentially harmful drug interactions, intercept inadvertent medication errors, and 
offer a patient-friendly printout of instructions.” 24 The authors note that this detailed process 
rarely occurs when doctors dispense free samples. Relating to this, Chimonas and Kassier note 
the possibility of inadequate documentation in patients’ records about the distribution of 
samples, and argue that this could cause issues with notifying patients in the event that the 
product is recalled or new drug complications are revealed. 24 They feel that this is especially 
troublesome given that many of the drugs that are offered as samples are newer products that 
are not time-worn and well-tested. They provide a specific example of a related situation that 
put patients at risk revealing that, “in 2004, four of the 15 medications most frequently given as 
samples to children in the US received new or revised ‘black box’ warnings from the US Food 
and Drug Administration within two years of approval.” 24 The last potentially negative impact 
discussed by multiple articles was that samples may drive health care costs. A JAMA article 
notes that the “availability of free samples is a powerful inducement for physicians and patients 
to rely on medications that are expensive but not more effective.”22 As mentioned previously, 
this is because the majority of samples that are provided are expensive brand-name drugs 
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rather than less expensive generic alternatives. Thus, when patients stop receiving samples, 
they ultimately pay higher prescription costs, and those indigent patients that the samples 
were intended to help find themselves in a predicament where they can’t afford their 
medication and must discontinue their treatment. All of these previously stated impacts 
seriously call into question whether the provision of samples is actually creating more positive 
effects than negative.  
Educational and Promotional Meetings 
The next largest portion of DTPP spending is dedicated to educational and promotional 
meetings. Pharmaceutical industry representatives invite physicians to meetings during which 
industry-paid physicians discuss the uses of particular drugs.10 In discussing this category of 
DTPP, this report will include activities where physicians attend any kind of industry-sponsored 
meeting, such as educational symposia, speaking events by pharmaceutical sales 
representatives, or industry-sponsored medical conferences. These meetings can be local, 
regional, state, national, or international, and sometimes, they are combined with vacation or 
recreational events such as trips to resorts or desirable cities. The author of The Truth About 
Drug Companies argues that many of the pharmaceutical industry’s DTPP efforts are masked as 
“education.”4 Angell argues that this allows pharmaceutical companies to categorize these 
expenditures as educational activities rather than promotional efforts, and feels that the 
amount of money spent on sponsoring these type of meetings is much higher than reported.4 
Pharmaceutical companies believe that physician-led meetings provide great education value. A 
Pfizer spokeswoman, Kristen Neese, noted, "We really do believe that these expert-led forums 
are a very valuable educational opportunity for them to learn about the experience of their 
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peers."27 According to an analysis conducted by ProPublica, eight pharmaceutical companies 
spent more than $220 million on promotional speakers for their products in 2010.28 Table 2 
provides detailed figures for the amount spent by the top pharmaceutical companies on 
speaker payments in during 2010. 












Attending these kinds of meetings is often very appealing to physicians, as the speakers are 
often leaders in their fields and many times they are held in attractive locations where there is 
nice food to go along with the information. According to the voluntary code of conduct adopted 
by the Pharmaceutical Researchers and Manufacturers of America, the meals served along with 
the educational meetings should be “modest” by local standards, but it appears that sometimes 
they exceed “modest.” For example, according to ProPublica, at least 20 doctors received meals 
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worth $2,000 or more from Pfizer between July 2009 and March 2010.28 Reporting the amount 
of money spent on “dining” physicians was made a requirement by the Sunshine Act and is 
available in the federally mandated database called the CMS Open Payments database, which 
was created by the Centers for Medicare & Medicaid Services.14  
Educational and Promotional Meetings: Impacts 
 Multiple studies have been conducted to reveal whether attending these industry-
sponsored lectures and meetings has an effect on physician behavior and attitudes. In the 2017 
review conducted by Fickweiler, Fickweiler, and Urbach, the authors found that these kinds of 
meetings did influence the behavior of the attendees, leading them to prescribe “more drugs 
from the sponsoring companies without sufficient evidence supporting superiority of those 
drugs.”18 In a troubling finding, the authors revealed that the majority of physicians who 
attended the sponsored meetings were not able to recognize inaccurate information about the 
company’s drug. Lastly, this study found that those “physicians who received money to attend 
pharmaceutical symposia or to perform research requested formulary addition of the 
company’s drug more often than other physicians.”18 In 2000, Wazana conducted an extensive 
study about physician interaction with the pharmaceutical industry, and her findings are similar 
to those of Fickweiler, Fickweiler, and Urbach. Wazana points out that often times, the 
pharmaceutical industry funds travel and lodging expenses for physicians to attend educational 
symposia.11 The study reveals acceptance of this kind of funding by physicians “was 
independently associated with increased formulary addition requests for the sponsor's drug.”11 
The study additionally found that “resident exposure to pharmaceutical representative 
speakers at lunch rounds was associated with dissemination and learning of inaccurate 
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information about the sponsor’s and competitor’s drug.”11 A systematic review published in 
2010, discussed similar findings about the impact of pharmaceutical company-sponsored 
meetings.23 The authors examined eight studies on this promotional practice and found that 
five of the studies revealed positive associations with prescribing frequency while the other 
three did not detect a significant association. 23 One of the studies that examined resident 
attendance at these meetings found that residents in attendance were more likely than their 
counterparts at the same hospital “to prescribe the sponsoring company's medication, both 
when it was appropriate according to the authors and when it was not.” 23 While 
pharmaceutical company-sponsored meetings serve an important informational purpose, 
further action must be taken to ensure that the content remains factual and unbiased, as it is 
clear these events impact the attitudes and behaviors of those physicians in attendance.  
Continuing Medical Education 
An indirect form of DTPP related to educational and promotional meetings is the 
funding of CME, or continuing medical education. Most states require doctors to receive CME 
throughout their professional lives in order to maintain their licenses. They earn these credits 
by attending meetings and lectures or participating in other CME activities each year in order to 
learn about the latest research and developments in their specialties. These meetings, lectures, 
and other activities must be provided through an accredited institution, and the Accreditation 
Council of Continuing Medical Education (ACCME) is responsible for accrediting the 
organizations that provide the programs. 4 Notably, it’s not usually the doctors who pay for 
their CME. In 2001, pharmaceutical companies paid for over 60% of the costs of continuing 
medical education.4 According to The Truth About the Drug Companies, in the past, 
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pharmaceutical companies directly supported the accredited professional organizations, “but 
now they often contract with private medical education and communication companies 
(MECCs) to plan the meetings, prepare teaching materials, and procure speakers.” 4 Many 
speculate that the reason that MECCs are accredited by the ACCME, despite controversy, is 
because the pharmaceutical industry and MECCs themselves make up half of the Task Force on 
Industry Professional Collaboration in Continuing Medical Education.4 This group of people are 
the ones responsible for helping the ACCME formulate policies on conflicts of interest.4  
There has been much debate over the past decades about the existence of a conflict of 
interest when pharmaceutical companies fund the organizations who are supposed to be 
providing evidence-based, impartial information about new medicines and treatments. 
According to Jerome Schofferman, a doctor from Daly City, California, CME meetings and 
lectures that are funded by the pharmaceutical industry have “the potential to unconsciously 
bias educators and the leadership of professional medical associations—biases that might 
unduly influence an attendee's choice of drugs and devices, and thereby ultimately affect 
patient care.”29 The existence of bias in the information presented by CME programs funded by 
Big Pharma is well documented, and their motives are less than subtle. One of the MECCs 
advertised its services with the statement, “Medical education is a powerful tool that can 
deliver your message to key audiences, and get those audiences to take action that benefits 
your product.”4 Basically, these organizations are advertising the fact that they have the ability 
to influence physicians to prescribe certain pharmaceutical products. Examples of potential 
biases that may exist in the information presented by pharmaceutical company-sponsored CME 
events include: “mentioning the sponsor's drug or device by trade name and competitor's 
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products generically; discussing off-label uses; minimizing disadvantages, side effects or 
complications; emphasizing positive papers while minimizing negative ones; omitting 
noncommercial forms of treatment; and over-reliance on personal experience.”29 Furthermore, 
pharmaceutical companies admit that they are selective in choosing what kinds of CME 
programs to fund. According to a JAMA article, “companies acknowledge that they carefully 
evaluate the market impact of expenditures and support only those demonstrating an 
increased use of their products.”22 
There are measures in place that attempt to prevent this bias. Speakers at these events 
are required to disclose their conflicts of interest or financial ties. But despite this requirement, 
it appears that simply disclosing that information does not eliminate the bias or make it 
acceptable. The Institute of Medicine (IOM) stated that “industry influence of choice of topics 
and content is not rare.” 29 Marcia Angell states that the pharmaceutical companies or the 
MECCs “often suggest the topic and the speaker and put together the graphics and other 
educational materials.”4 In an article from the Journal of Pediatrics and Child Health, the author 
discusses a related topic, noting that there is substantial evidence indicating that “industry-
sponsored CME activities are more focused on drug therapies and are more favorable to 
company products than programs not funded by industry.”30  
As the debate on this controversy has intensified, it seems as though pharmaceutical 
companies have pulled back on the amount of funds that they dedicate to continuing medical 
education courses. In the summer of 2008, Pfizer was the first pharmaceutical company to 
make a drastic move away from funding CME programs.31 The company made substantial 
cutbacks on their financial support of CME and announced that it would “support programs run 
 40 
by academic institutions, teaching hospitals, and medical societies, but eliminate direct financial 
support for courses offered by for-profit medical education companies.”31 According to a Pew 
Research article, “in 2011, the pharmaceutical and medical device industries provided 32% of 
all funding for continuing medical education courses in the United States—$752 million out of 
$2.35 billion.”10 This substantially decreased from the 60% of funding they provided in 2001, 
but there is still a significant effort to completely eliminate pharmaceutical industry funding of 
these programs. In 2007, the Senate Finance Committee released a report on drug industry 
CME grants. The creation of this report was sparked by the Committee’s “belief that the 
pharmaceutical industry uses educational grant funding to promote the use of their drugs, 
including unapproved uses of some medicines.”32 According to this article, the release of this 
report was likely to further the government’s efforts to restrict the pharmaceutical industry’s 
involvement in CME and their use of these programs to transmit off-label information (the use 
of their products for reasons not approved by the FDA).32 In an article from the Journal of 
Pediatrics and Child Health, Ian Kerridge notes that “recent reports by the Josiah Macy Jr 
Foundation, the Institute of Medicine, the American Medical Association (AMA) Council on 
Ethical and Judicial Affairs and the Association of American Medical Colleges have all called for 
the establishment of independent CME that either operates completely at arm's length to 
industry or receives no commercial support at all.”30 According to an article from Policy Med, it 
appears that only two Academic Medical Centers (AMCs), the University of Michigan and 
Memorial Sloan-Kettering Cancer Center, have stopped accepting funding from pharmaceutical 
and medical device companies.33 Moreover, the ACCME has announced that it would “not be 
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taking any action to end the commercial support” of accredited CME, but rather it planned to 
enhance it monitoring system to ensure compliance.33  
CME: Impacts 
The reason that pharmaceutical companies continue to pour resources into CME despite 
the intense controversy is because it is effective, and the industry argues that it produces a 
number of positive effects. Many individuals claim that industry funding of these programs 
results in greater CME participation by keeping the cost of attendance down and also by making 
the meetings more enjoyable by providing things such as free meals. They argue that, in turn, 
industry funding of CME benefits patients by improving physician knowledge and 
competence.31 That being said, there is little evidence to indicate whether industry funding of 
CME benefits physicians and patients in these ways, but many studies have produced evidence 
indicating its potential to influence physician knowledge, attitudes, prescribing behavior.  
According to a study outlined in a 2017 BMJ article, those physicians who attended 
company-sponsored CME events had more positive attitudes toward the pharmaceutical 
company or product and had an inclination to prescribe the branded-product. 18 Additionally, 
the article noted that those physicians who refused CME sponsorships, “were seen to prescribe 
higher proportion of generics and lower expenditure medicines when compared with physicians 
who attended CMEs.”18 The study conducted by Wazana in 2000 also focused on the impact of 
CME sponsorship by pharmaceutical companies.11 Wazana’s results emphasized the previously 
stated notion that pharmaceutical company-sponsored CME events preferentially highlight the 
sponsor’s drug(s) compared to other CME programs not sponsored by the industry. 11 
Additionally, physicians self-reported the fact that there were changes in their prescribing 
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practices in favor of the sponsor’s drug after attending CME events. 11 Lastly, the article notes 
that physician attendance of sponsored CME events was associated with increased prescription 
rates of the sponsor’s medication.11 Industry funding of CME has an undeniable influence on 
the content of the education that physicians are receiving, and in turn an undeniable influence 
on their prescribing behaviors. It appears from the actions already taken by Pfizer and a few 
Academic Medical Centers that this influence may be ethically questionable, and it will be 
interesting to observe how the medical industry proceeds in coming years.  
Gifts 
The next aspect of DTPP that this report will address is not technically its own category 
of promotion, but rather a component of all the promotional efforts I previously mentioned. It 
is widely documented that physicians receive “gifts” from the pharmaceutical industry, and 
these gifts come in many forms. Pharmaceutical sales representatives distribute small, 
inexpensive “reminder” items such as pens, notepads, and coffee mugs labeled with the 
pharmaceutical company’s name or product. Pharmaceutical companies additionally distribute 
more “moderately priced gifts (valued at $20 to $100), such as reference tools, books and 
meals.”34 A systematic review conducted by Fickweiler, Fickweiler, and Urbach in 2017 revealed 
that the most common gifts received by physicians were “medical samples, promotional 
material, invitations for dinners, invitations for CMEs, scientific journals and free lunches.”18 In 
the past, pharmaceutical companies provided much more expensive gifts such as “tickets, trips, 
and large ‘honoraria’ for participation in pharmaceutical-sponsored activities.” 34 These types of 
gifts became much less common after the Sunshine Act was passed in 2010 as part of the 
Affordable Care Act. As mentioned earlier in this report, this act “requires medical product 
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manufacturers to disclose to the Centers for Medicare and Medicaid Services (CMS) any 
payments or other transfers of value made to physicians or teaching hospitals.”14 
Pharmaceutical companies report this data annually and it is published in a publicly searchable 
database called CMS Open Payments.14 
While the government has increased regulation of high-value gifts, the pharmaceutical 
industry still regularly dispenses gifts within the required price limits. A 2006 analysis from 
Science Direct explains that pharmaceutical advertising items are frequently found in the coats 
of resident physicians. 34 The cited study revealed that “97% of 164 house officers studied 
carried at least 1 item with pharmaceutical insignia.”34 Physicians begin receiving gifts from the 
pharmaceutical industry very early in their careers, and the frequency and forms of gifts 
received vary as they evolve into different positions within the medical hierarchy. One study 
found that residents typically receive about 6 gifts a year. 11 While there was no comparable 
data in this study for physicians, it is generally understood that as physicians enter practice, the 
gifts they receive are more related to research funding, honoraria, and conference travel. 11 
Another study conducted in 2013 directly analyzed the interactions between physician trainees 
and the industry and found that “among 1,610 student (49.3 % response rate) and 739 resident 
(43.1 %) respondents, industry-sponsored gifts were common, rising from 33.0 % (first-year 
students) to 56.8 % (fourth-year students) and 54 % (residents). These gifts included meals 
outside the hospital (reported by 5 % first-year students, 13.4 % fourth-year students, 27.5 % 
residents) and free drug samples (reported by 7.4 % first-year students, 14.1 % fourth-year 
students, 14.3 % residents).”35 As gifts from the pharmaceutical industry take on a number of 
different forms, it is hard to measure the exact amount of resources dedicated to this practice. 
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Nevertheless, it is clear that the number is significant and that the practice plays a vital role in 
gaining the favor of physicians. Michael Oldani, an anthropologist and former pharmaceutical 
sales representative, notes, “the importance of developing loyalty through gifting cannot be 
overstated.”15 
Gifts: Impacts 
 A number of studies have documented that gifts from the pharmaceutical industry (of 
any value) have a significant impact on physician’s attitudes and prescribing behavior. 
Moreover, physicians have different attitudes towards the practice of gifting by the industry. 
Some readily accept gifts while others adopt strict avoidance policies. Wazana revealed that 
“85% of medical students believe it is improper for politicians to accept a gift, whereas only 
46% found it improper for themselves to accept a gift of similar value from a pharmaceutical 
company.” 11 It seems that most doctors are positioned in the middle of the two extreme 
attitudes, finding that some forms of gifts are appropriate while others are not.  Fickweiler, 
Fickweiler, and Urbach found that physicians usually consider “conference registration fees, 
informational luncheons, sponsorship of departmental journal clubs, anatomical models and 
free drug samples” as appropriate gifts.18 The authors also reveal that the majority those 
doctors who do accept gifts consider themselves immune to the influence of gifts.18 Although 
they may feel this way, studies have documented that this assumption is not accurate. To this 
point, Wazana found that “receiving a gift and the number of gifts received correlated with the 
belief that pharmaceutical representatives have no impact on prescribing behavior.” 11 It 
appears that as physicians receive more gifts, they either become more oblivious or more 
willing to overlook the potential influence on their behavior. 
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 The pharmaceutical industry and physicians defend the practice of gift exchange by 
citing the Sunshine Act, claiming that small gifts do not influence physician behavior and that 
disclosure of financial conflicts of interest protect patients’ interests. But many individuals call 
into question the validity of these assumptions, and argue that requirements of the Sunshine 
Act are not enough to eliminate potential conflicts of interest. These authors cite studies that 
reveal that gifts of any value (no matter how small) impact physicians by inducing reciprocal 
feelings. Authors of a 2006 JAMA article explain that, “social science research demonstrates 
that the impulse to reciprocate for even small gifts is a powerful influence on people’s 
behavior.”22 The authors go on to explain that “individuals receiving gifts are often unable to 
remain objective; they reweigh information and choices in light of the gift.”22 In this discussion, 
the authors emphasize that the primary reason for gift giving is often the expectation of 
reciprocity.22 Thus, these authors argue that the requirements of the Sunshine Act are not 
enough to resolve the issues created by physician’s acceptance of gifts from the pharmaceutical 
industry. The gifts of small value that continue to be distributed are influencing physicians’ 
attitudes and behaviors. The article cites study results concluding that “receiving gifts is 
associated with positive physician attitudes toward pharmaceutical representatives.”22 
Moreover, the authors reveal that “physicians who request additions to hospital drug 
formularies are far more likely to have accepted free meals or travel funds from drug 
manufacturers.” 22 A 2016 study examined the association between physicians’ receipt of 
industry-sponsored meals and rates of prescribing the promoted drug to Medicare 
beneficiaries.59 The authors found that “physicians who received a single meal promoting the 
drug of interest, with a mean value of less than $20, had significantly higher rates of prescribing 
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rosuvastatin as compared with other statins; nebivolol as compared with other β-blockers; 
olmesartan as compared with other angiotensin-converting-enzyme inhibitors and angiotensin-
receptor blockers; and desvenlafaxine as compared with other selective serotonin and 
serotonin-norepinephrine reuptake inhibitors.”59 This finding strongly indicated that those 
physicians who receive industry-sponsored meals or payments are much more likely to 
prescribe the promoted brand-name medication to Medicare patients at an increased rate. This 
study also supports the claims made in the 2006 JAMA article22, that even gifts of small value 
have a substantial impact. From the evidence presented throughout these studies, the impact 
of gifting is clear, and it may be time for the government to consider heightening the 
restrictions set forth in the Sunshine Act.   
Journal and Web Advertisements 
 One of the last prominent categories of DTPP that this report will discuss is the 
publication of advertisements in medical journals (many of which are increasingly online). 
These advertisements provide an important source of revenue for medical journals and in early 
years, journal advertising was the pharmaceutical industry’s most effective source of 
promotion. According to one study, “journal advertising generated the highest return on 
investment of all promotional strategies employed by pharmaceutical companies, with returns 
ranging from $2.22 to $6.86 per advertising dollar spent between 1995 and 1999.”10 In recent 
years, these advertisements have received less funding than other promotional activities such 
as detailing and sampling. According to Schwartz and Woloshin, pharmaceutical spending on 
medical journal advertising declined from $744 million in 1997 to $119 million in 2016.1 While 
spending in this area has declined, it remains an attractive marketing technique because a large 
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majority of physicians continue to utilize medical journals as an important source of 
information. According to a 2018 article, print versions of these journals reach 90% of 
physicians, and when combined with digital versions, they reach 96% of physicians.36 Milton 
Liebman, president of the Association of Medical Publishers, emphasizes this point in his 
statement, “Print promotion usually provides higher message penetration than detailing 
because print (most notably journals) obtains higher reach into the target audience with great 
consistency of message delivery.”37 Moreover, journal advertising acts as a very effective 
complementary promotional effort when combined with the practice of detailing. Marshal Paul, 
chairman of PERQ/HCI Research which conducts media research for the pharmaceutical 
industry, stated, “Advertising magnifies the detailing effort at a fraction of detailing expense. In 
effect, detailing provides the power in the marketing effort and advertising provides the 
efficiencies.” 37 In the integrative review conducted by Manchanda and Honka in 2005, they 
discuss evidence that emphasizes the notion that physicians still heavily utilize medical 
journals.19 The authors note a 1980 study that involved a survey of “general practitioners on 
their most recent, regular, and most useful sources of information about therapeutics and 
prescribing.”19  All of the respondents ranked journals first on all three criteria (recency, 
regularity, usefulness).19 This review goes on to cite multiple studies that indicate the extent to 
which physicians rely on medical journals, but many of the referenced sources are significantly 
dated. Physician reliance on printed medical journals as a source of information may have 
decreased in recent years, but it is still imperative that these sources are distributing factual, 
unbiased information.  
 48 
 In recent years, there has been growing concern about the quality of the information 
published in medical journals by the pharmaceutical industry. The U.S. Food and Drug 
Administration (FDA) is the party responsible for regulating the accuracy of the advertisements 
published in medical journals, and over the years, they have grown increasingly critical of 
pharmaceutical advertisements. Their most common complaint is that the industry often 
publishes advertisements that highlight the effectiveness of their products without pointing to 
the risks. Specifically, in April 2009, the “FDA warned 14 major drug makers for running search 
ads for many of their products that highlighted the products' effectiveness without noting any 
of their risks.”10 Schwartz and Woloshin discuss a 2008 study of advertising in nine “high-impact 
journals.”1 The results of the study revealed that 58% of the advertisements “did not quantify 
serious risks, 48% lacked verifiable references, and 29% did not quantify efficacy.”1 Moreover, a 
PubMed review analyzed 109 full-page pharmaceutical advertisements and “concluded that 
44% would lead to improper prescribing if a physician relied only on the information presented 
in the advertisement.”38 In a 2006 PLOS Medicine article, the authors argue against the industry 
claims of the educational value of their advertisements.37 The authors note that while there are 
more than 10,000 drugs in the US market, over half of pharmaceutical journal advertisement 
expenditures are spent on the 50 best-selling drugs, and they additionally emphasize the 
promotion of new drugs.37 They argue that “new” and “best-selling” drugs are not always 
superior to old or competing drugs, invalidating the “educational-value” claim.37 None of the 
medical journals require companies to demonstrate product superiority in their ads, making it 
questionable as to whether these ads are really enhancing the prescribing decisions of 
physicians. Additionally, these authors remain skeptical about the quality of the data and 
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studies cited within these advertisements. In this discussion, they note a 2005 study of ads in 10 
US medical journals conducted by Cooper and Schriger.37 They reveal that, “Of 312 
advertisements with references, 55% cited journal articles and 19% cited ‘data on file’ 
(proprietary information that companies are not obligated to provide to clinicians).”37 
Moreover, “only 20% of references to data on file were available.” The authors also explain that 
many of the studies cited in the advertisements are sponsored by the pharmaceutical industry, 
creating the potential for biased results.37 In the 2005 study by Cooper and Schriger, “58% of 
original research cited was sponsored by or had an author affiliated with the product 
manufacturer, compared with 8% of references to original research within research articles.”37 
There have been a number of allegations of pharmaceutical companies withholding or failing to 
report negative data when marketing their products, and subsequently a number of individuals 
have become skeptical of the of the information presented in journal ads. This growing concern 
has caused important medical journals to reconsider their advertising relationship with the 
pharmaceutical industry. According to a Nature Biotechnology article, “Journals like the British 
Medical Journal have considered banning all submissions from industry authors; the Lancet and 
the New England Journal of Medicine decline to publish any review articles by industry authors; 
and several clinical conferences no longer allow big pharma speakers to present their results.”26 
As clearly presented in subsequent evidence, it is not hard to find a pharmaceutical 
advertisement in a medical journal that presents biased or nonfactual information, and it is for 
this reason that clinical journals and learned societies are considering such extreme measures 




The last major area of DTPP that this report will address is promotional mailings. This 
promotional practice involves sending promotional materials and brochures to physicians’ 
offices. While investment in this form of marketing pales in comparison to investment in other 
promotional areas, in 2012, $1.2 billion of the pharmaceutical marketing budget was spent on 
producing and distributing these materials.10 There has been a substantial amount of literature 
written about the pharmaceutical practice of promotional mailings, and many authors question 
the quality of the information presented in the brochures. Authors of a 2006 BMC article 
conducted a study in which they asked physicians from five clinics to send all of the 
promotional mailings they received to one centralized location.39 These materials were 
subsequently examined by two “blinded-reviewers” who compared the information presented 
in the brochures to the data found in the original study. After reviewing a total of 20 distinct 
promotional brochures, the reviewers found that “75% of the studies were found to be valid, 
80% were funded by the pharmaceutical company, 60% of the studies and the corresponding 
brochures presented patient-oriented outcomes, and 40% were compared to another 
treatment regimen.”39 Furthermore, “Of the 19 brochures that presented the data as graphs, 4 
brochures presented a relative risk reduction while only 1 brochure presented an absolute risk 
reduction.”39 Lastly, “15% of the promotional marketing brochures presented data that was 
different from what was in the original published study.”39 As this study revealed, the majority 
of the cited studies in these brochures are funded by the pharmaceutical company themselves. 
This finding is troubling when considering the article’s additional finding that those “studies 
that were sponsored by pharmaceutical companies were four times more likely to have 
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outcomes favoring the sponsor's product than were studies that had other types of sponsors.”39 
It appears that many individuals become more skeptical about the validity of studies 
highlighted in promotional mailings when they are funded by the industry. Another commonly 
noted complaint about promotional mailings is that pharmaceutical companies “selectively 
report trials in which the sponsored drug out performed that of competitors.”10 This criticism 
was similarly brought forth in the previous discussion about pharmaceutical advertisements in 
medical journals. It appears from the overwhelming complaints existent in today’s literature 
that there is a growing need for more stringent evidence-based review of pharmaceutical 
promotional material distributed in all settings, whether it be promotional mailings, journal 
advertisements, or pharmaceutical sales representative speeches.  
 After thoroughly examining each of the promotional tactics used by the pharmaceutical 
industry to target physicians, it appears that while there are some benefits of DTPP, there are 
also a number of issues that need to be resolved. The practice of detailing, sampling, and 
providing gifts of any form to physicians, puts doctors in a situation where their medical and 
moral obligations may be compromised. It is clear these promotional tactics influence the 
prescribing behavior of physicians whether they realize it or not, and the government, the 
pharmaceutical industry, and the medical community as a whole must consider DTPP’s 
potential impact on patient care. While there are regulations and guidelines in place, it appears 
that there are still existing conflicts of interest, and these parties must work harder to resolve 
these issues and protect the interest of patients. The other apparent issue with the practice of 
DTPP is the quality of the educational content being distributed. Doctors rely on the 
pharmaceutical industry in a number of ways to enhance their knowledge and practice, but it 
 52 
appears that the information they are receiving is not always unbiased and factual. It is 
important for doctors to continue to learn about the latest advances in medicine from the 
pharmaceutical industry, but regulatory agencies must work harder to ensure that the 
educational content distributed by the industry is grounded in science and not biased to 
promote a particular product or company.  
Part III: Direct to Consumer Advertising 
 While Direct to Physician Promotion has been employed for decades, in more recent 
years, pharmaceutical companies have rapidly increased their use of Direct to Consumer 
Advertising. Direct to Consumer Advertising (DTCA) is the practice of marketing and advertising 
pharmaceutical products directly to consumers as patients via mass media platforms. The 
United States and New Zealand are the only two countries that currently allow DTCA that 
includes product claims. Canada allows pharmaceutical companies to employ DTCA that 
mentions either the product or the indication but not both.40 Besides these three countries, the 
rest of the world has completely outlawed the pharmaceutical practice of DTCA. This fact alone 
should indicate that there is considerable controversy surrounding the practice of marketing 
prescription medication directly to consumers. An enormous volume of literature has been 
written on the subject of DTCA. Authors hold a variety of opinions on the practice and a 
number of studies have been conducted that reveal evidence supporting both sides of the 
argument. This report will go into more detail later on about the pros and cons of 
pharmaceutical marketing and the corresponding evidence, but before one can develop an 
opinion on the subject, it is important to have a thorough understanding of the practice as a 
whole. Regardless of the arguments presented by DTCA advocates or DTCA critics, it cannot be 
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denied that the inherent goal of advertising it to drive profits. Thus, at its foundation, the aim of 
DTCA is to encourage consumers to request the advertised medication from their physicians 
and subsequently increase prescription medication sales. Whether these advertisements are 
actually creating a more informed, empowered, and responsible healthcare consumer will be 
subsequently discussed, but their effect on the pharmaceutical industry’s profits are clear. 
Direct to Consumer Advertising is the fastest growing segment of pharmaceutical marketing 
spending as indicated by the high prevalence of television ads for prescription medications. But 
why now? No federal law has ever banned Direct to Consumer Advertising, so when and why 
did these advertisements become so pervasive?   
Background and Regulation 
 In 1981, the first Direct to Consumer Advertisement was printed in Reader’s Digest by 
Merck to advertise its new antipneumococcal vaccine, Pneumovax.40 During this time period, 
the U.S. political climate became more favorable to deregulation and in turn, to pharmaceutical 
companies. Additionally, a cultural shift occurred that caused patients to take a more active 
role in their health care decision making. Thus, pharmaceutical companies began to increase 
their DTCA efforts. From 1980 to 1990, total spending on DTCA increased from $12 million to 
$47 million, and by 1995, it had increased to $340 million. 40 But this 3,000% increase over 15 
years pales in comparison to the boom in DTCA after 1997. 40 It was in this year that the Food 
and Drug Administration relaxed the guidelines for prescription drug advertisements, and 
subsequently, the budgets for DTCA more than tripled to $1.2 Billion in 1998.40 Prior to 1997, 
the FDA’s regulations mandated that prescription drug advertisements “(1) not be false or 
misleading, (2) present a ‘fair balance’ of information describing both the risks and benefits of a 
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drug, (3) include facts that are ‘material’ to the product’s advertised uses, and (4) include a 
‘brief summary’ that mentions every risk described in the product’s labeling.”40 Describing 
every risk and including the complete information to satisfy the “fair balance” and “brief 
summary” regulatory requirement was very time consuming, making broadcasts ads very 
costly.40 The FDA recognized that the cost of purchasing enough time to include all of the 
necessary information was prohibitive, and subsequently issued draft guidance on this topic in 
1997.40 With the new rules, broadcast DTC product claim ads only had to include the “major 
risks” and an “adequate provision” that would direct the viewers to a place where they could 
access a complete “brief summary.”40 This new relaxed set of rules triggered a boom in the 
pharmaceutical DTCA efforts that have persisted through today.  
Categories of DTCA and Current Regulation 
 Direct to Consumer Advertisements are generally characterized into three categories: 
“Product-Claim,” “Reminder,” and “Help-seeking.” The FDA recognizes these categories and has 
created specific requirements based on each category. Product-Claim advertisements are the 
most common. They name a drug and make a therapeutic claim about the product. Product-
claim advertisements must include: “the name of the drug, at least one FDA-approved use for 
the drug, and the most significant risks of the drug.”41 Additionally, they must present the risks 
and benefits of the drug in a balanced fashion to satisfy the “fair balance” requirement.41 While 
print product-claim advertisements must also include a “brief summary” about the drug that 
includes all of the risks, the FDA makes an exception for broadcast ads because of the 
prohibitive nature of the time expense. Broadcast product-claim advertisements must only 
include a “major statement” of the most important risks and provide consumers with access to 
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more complete information.41 This is usually satisfied by providing a toll-free telephone 
number, a health care provider’s contact information, a Web site address, or a link to a 
concurrently running print advertisement with the complete information.41 
Reminder advertisements name a specific drug, but they do not reference the health 
condition the drug is used to treat. These ads assume that the audience already knows the 
drug’s use, so they are typically directed at health care professionals. A reminder ad does not 
have to include information about risks (nor can it include anything about benefits), because 
the advertisement does not state what the drug does or how well it works. However, the FDA 
does not allow these types of advertisements for prescription drugs with serious risks. These 
drugs have a special warning, often called a “boxed warning,” in the drug’s FDA-approved 
prescribing information.41 
Help-Seeking advertisements describe a particular disease or health condition and 
advise the consumer to see his/her doctor, but they do not recommend or suggest a specific 
drug treatment. Properly done help-seeking advertisements are not technically considered drug 
advertisements, as they do not mention a specific product.42 
Pharmaceutical companies are required to submit copies of their advertisements to the 
FDA before they are published or aired, but no preclearance approval is required. That being 
said, if after airing, the FDA finds that an advertisement violates an FDA provision, it can issue 
letters of violation. While they can issue letters, the current system does not allow the FDA to 
issue fines to violating pharmaceutical companies unless they call for an administrative 
hearing.9 This regulatory process is supposed to protect consumers and hold drug companies 
accountable for the information they distribute. In addition to government regulation, PhRMA 
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(Pharmaceutical Research and Manufacturers of America) has created a set of guidelines for the 
practice of DTCA. These guidelines state that pharmaceutical companies should “spend an 
appropriate amount of time on physician education prior to running DTC ads.”9 Additionally, 
the guidelines recommend that “companies should submit all new DTC advertisements to the 
FDA before releasing these advertisements for broadcast.”9 Lastly, the guidelines explain that 
DTC advertisements should “contain information about the availability of other options such as 
diet and lifestyle changes where appropriate and that DTC ads should be presented in clear, 
understandable language, without distraction from the content.”9 It must be emphasized that 
these guidelines are simply a recommendation and by no means an enforceable requirement. 
The relaxed regulations and arbitrary guidelines that pharmaceutical companies adhere to 
when using DTCA today have allowed pharmaceutical companies to directly market their 
products to consumers in a variety of ways to exponentially drive profits in recent years.  
Spending 
An in-depth study of medical marketing in the United States found that the most rapid change 
in spending from 1997 to 2016 was for DTC advertising, which increased from $1.3 billion 
(79,000 ads) to $6 billion (4.6 million ads [including 663,000 TV commercials]), accounting for a 
361% increase.1 While pharmaceutical companies are rapidly investing more resources in DTCA, 
the $6 billion spent on DTCA in 2016 represented only 20% of the total medical marketing 
expenditure ($29.9 billion), as the majority of the budget is still allocated to Direct to Physician 
Promotion (DTPP).1 Figure 7 illustrates DTCA spending by the pharmaceutical industry during 
the 1997 to 2016 time period.  
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       Figure 7. DTCA Spending from 1997-201658  
 
As illustrated in Figure 7, the DTCA declined from 2016 to 2017, and this is largely due to the 
fact that the industry lost some of its biggest DTC spenders due to the loss of exclusivity.58 As 
the practice of DTCA is relatively new with respect to the long history of pharmaceutical 
promotion, the gap between investment in DTCA versus DTPP is still large. Nonetheless, DTCA 
has proven to be extremely effective in driving prescription sales and in turn profit. A study 
conducted in 2000 found that every dollar the pharmaceutical industry spent on DTCA yielded 
an additional $4.20 in drug sales.43 Furthermore, the study revealed that DTCA “was 
responsible for 12% of the increase in prescription drugs sales, or an additional $2.6 billion, in 
2000.”43 Tsai and Lancaster, authors of a 2012 analysis, note that, “brands with high DTC 
spending are typically among the best-selling drugs” and additionally, “a closer look at the sales 
data of prescription medicine reveals that, among the 50 most heavily advertised drugs, the 
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number of prescriptions dispensed rose 25% between 1999 and 2000, compared to a mere 4% 
increase for other drugs.”44 An article from Forbes noted that the “2008 House Commerce 
Committee found that for every $1,000 spent on prescription drug ads, 24 new patients were 
added for the pharma industry.”45 This author additionally explained that “a 2003 research 
report found that rates for prescription drugs with ads were almost seven times greater than 
for those without ads.”45 A systematic review published in the BMJ examined two interrupted 
time series studies in the US that revealed a “a significantly increased trend in the prescribing 
volume of drugs that had been the subject of DTCA campaigns.”46 Furthermore, the study 
indicated that “the effect of DTCA seemed to both increase the number of new diagnoses of a 
condition and tended to increase the proportion of prescriptions specifically for the advertised 
drug.”46 Numerous studies reveal that DTCA is having its intended effect of driving sales and 
profits, and it is clear why DTCA is the fastest growing segment of pharmaceutical marketing.  
Trends and Timing 
While DTCA may appear to be a ubiquitous practice utilized by the pharmaceutical 
industry as a whole, research has revealed that spending on DTCA has been concentrated 
amongst a relatively small number of brands. Authors of an article in The New England Journal 
of Medicine uncovered this finding in a detailed analysis they conducted of industry-wide trends 
in spending by pharmaceutical companies on DTCA.47 The authors noted that “the 20 drugs 
with the highest (DTCA) spending made up 54.4% of total industry spending on [DTC] 
advertising in 2005.”47 The authors additionally examined a number of specific drugs and their 
associated advertising spending. They revealed that “in 2005, 8 of the 10 top drug classes in 
terms of dollar sales had at least one product with advertising spending.”47 They gave specific 
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examples of drugs with higher DTC advertising budgets and explained that “manufacturers of 
proton-pump inhibitors, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors (statins), and erythropoietin medications spent 34%, 34%, and 31% of their total 
marketing budget, respectively, on direct-to-consumer advertising in 2005.”47 Compared to 
advertising spending for these medications, the authors found advertising spending for 
antidepressant agents, seizure-disorder medications, and antipsychotic agents to be lower.47 
Schwartz and Woloshin additionally analyzed DTCA spending across specific therapeutic 
categories in their analysis of medical marketing in the United States between 1997 and 2016.1 
The authors found that during this time period, DTCA spending for prescription drugs increased 
across all therapeutic categories, except for allergy, cholesterol, and osteoporosis drugs.1 Figure 
8 displays detailed information about the trends in DTCA spending for specific therapeutic 
categories.   











The authors found that DTCA spending for allergy, cholesterol, and osteoporosis drugs declined 
during this time period because the top-selling drugs lost patent protections or became 
available over the counter “without replacement by equally large advertising campaigns for 
new drugs in the category.”1 They additionally found that the greatest spending increases 
during this time period were associated with drugs for “diabetes/endocrine diseases, 
dermatology conditions, pain/central nervous system disorders, arthritis, cardiac diseases and 
cancer, largely reflecting competition among expensive new biologics and cancer therapies.”1  
However, the author of The Truth About Drug Companies makes a broad statement about the 
type of drugs advertised in 2006, stating that “most (DTC) ads do not introduce drugs for rare or 
previously untreatable conditions but rather promote drugs for well-known conditions for 
which there are plenty of treatments already at hand.”4 
The authors of The New England Journal of Medicine article found that the medications 
most prominently and frequently advertised to consumers in 2007 were new drugs used to 
treat chronic conditions.47 To this point, the authors examined trends in timing of DTCA. They 
reveal that DTCA campaigns “generally begin within a year after the approval of a product by 
the FDA.”47 The authors note this finding as a cause for concern, explaining that it “raises 
questions about the extent to which advertising increases the use of drugs with unknown safety 
profiles.”47 The authors mention multiple parties that have come forward and expressed 
apprehension about the advertising of drugs that are not time-worn and well-tested to 
consumers. They note that, “At least one pharmaceutical manufacturer (Bristol-Myers Squibb) 
recently announced a voluntary moratorium on direct-to-consumer advertising for drugs in the 
first year after FDA approval.”47 The authors additionally reveal that “PhRMA, the industry 
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trade group, has recommended that manufacturers delay such campaigns for new drugs until 
after health professionals have been sufficiently educated, although no details have been 
provided on how long a period was deemed necessary.”47 Lastly, the “Institute of Medicine 
called for a 2-year moratorium on DTCA for newly approved drugs in 2007, and the American 
Medical Association voted in favor of a ban on DTCA in 2015.”48 With that being said, no action 
has been taken to prohibit pharmaceutical companies from advertising new drugs with 
unknown safety profiles.  
Media Distribution Channels 
The relaxation of the FDA rules after 1997 not only affected the amount pharmaceutical 
companies were spending on DTC advertisements but also the media channels through which 
they were distributed. Figure 9 displays the spending on Direct to Consumer Advertising for 
prescription drugs and health services from 1997 to 2016, categorized by media distribution 
channels. 
Figure 9. DTCA Spending by Media Distribution Channel 1997-20161 
 
Pharmaceutical companies traditionally distribute DTC ads via tv, radio, magazines, 
newspapers, billboards, and lastly, they are increasingly making use of the internet as an 
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effective dissemination channel. The two main types of advertisements this report will discuss 
in depth are television advertisements and internet/social media advertisements. This is 
because, as depicted in the previous graph, the majority of the DTCA budget is spent on 
television commercials, and internet/social media advertisements are proving to be one of the 
fastest growing components of DTCA.  
Television 
While the large increase in spending on TV advertisements from 1997 to 2016 coincides 
with a shift to more costly television commercials, it is also representative of an increase in the 
number of ads. During this time period, the number of television commercials increased from 
72,000 to 663,0000.1 According to Nielson, “in 2009, the pharmaceutical industry was the 
second largest product category by ad spending with approximately $4.5 billion in advertising 
expenditure, second only to the automotive industry.”44 In 2011, the average American 
television viewer watched as many as nine drug advertisements a day, totaling to 16 hours per 
year. This number far exceeds the amount of time the average American spends with a primary 
care physician.40 The number of ads, and in turn, the amount of time spent by Americans 
viewing these ads has increased exponentially into 2019. Numerous studies have analyzed the 
nature of televised DTCA ads due to their increasingly pervasive nature.  
Nature of Televised DTCA 
Over the years, the DTCA landscape has evolved as a number of noteworthy 
controversies have resulted from televised DTCA. Applequist and Ball discuss some of these 
controversies including “the recall of Vioxx in 2004 and the revelation that ads falsely depicted 
the Lipitor spokesperson, Dr Jarvik, as a licensed physician.”48 This report will subsequently 
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discuss the details of these controversies when considering the negative ramifications of DTCA. 
Moreover, the authors explain that regulation has evolved as the FDA published the 
Amendments Act of 2007 which “required drug makers to submit television advertisements 45 
days before the first airing” and additionally, the agency “drafted updated guidance to 
standardize the appearance of drug brand names, to clarify points regarding the fair and 
balanced presentation of benefit and risk information, and to specify regulatory guidelines to 
be applied to online advertisements.”48 Due to these significant events, the authors felt that a 
more updated analysis of DTC television advertisements was necessary to investigate whether 
these events had an effect on the content of prescription drug commercials. In turn, Applequist 
and Ball examined pharmaceutical advertisements that appeared on 4 major US television 
networks over a 13-week period in 2016.48 After sifting through 868 DTC product claim 
advertisements that aired during the collection period, the authors removed duplicates and 
analyzed a total of 61 unique product claim advertisements for 35 prescription drug brands.48 
This report will discuss the results of this study in detail, as it appears to be the most recent and 
thorough analysis of current DTC television advertisements. The majority of DTC television 
advertisements are product-claim ads, as advertisers have recognized that the other two types 
(reminder and help-seeking) can be confusing and are less effective in terms of driving sales.44 
After the collection period, Applequist and Ball examined a number of different characteristics 
of the 2016 TV advertisements and compared their findings to commercials from a similar study 
conducted in 2004.  
 First, the authors found that while the advertisements have become 30% longer, their 
potential education value has declined.48 They note that the gap between the educational and 
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promotional content has increased, with more emphasis on the promotional content. They 
revealed that the “2016 ads conveyed a greater emphasis on the reported drug benefits at the 
expense of information about the health condition.”48 Furthermore, they explain that fewer of 
the 2016 ads “provided information related to the biologic nature, risk factors or causes, or 
prevalence of the condition compared with the 2004 sample.”48 Additionally, the authors noted 
a shift in the way the advertisements describe the prevalence of the condition.48 Rather than 
describe the conditional prevalence in quantitative terms (such as 1 in 4), more advertisements 
use qualitative descriptions such as “thousands” or “many.”48 The authors also examined the 
frequency with which the advertisements used rational and positive emotional appeal. They 
discovered that the frequency of these appeals remained consistent between the 2004 and 
2016 ads, but that there was a decrease in the use of negative emotional appeals.48 Positive 
appeal often involved portraying the patient’s happy mood after taking the advertised 
medication, while negative appeal often involved portraying the patient’s experience with the 
medical condition before taking the product. 
Another characteristic the authors examined was “lifestyle portrayals.” The authors 
revealed that, “the 2016 ads had increased portrayals of medical conditions interfering with 
healthy or recreational activities and of the product enabling healthy or recreational 
activities.”48 Additionally, they found that, “physical activity was featured in 58% of the 2016 
ads, with characters shown engaging in moderate or vigorous physical activity, such as 
bicycling, hiking, running, or playing sports.”48 Applequist and Ball also point out that many of 
the advertised conditions had treatment options that involve some behavioral change, but 
“none of the ads offered behavioral change as an alternative to taking medication and fewer 
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ads in the 2016 sample presented the drug as a beneficial addition to lifestyle changes such as 
diet and exercise.”48 
The last characteristic of the advertisements that the authors analyze is “medication 
portrayals.” Applequist and Ball found that almost all of the advertisements “portrayed a 
character regaining control as a result of obtaining a prescription drug.”48 They further explain 
that, “all ads that portrayed a loss of control due to the condition (59.7%) offered the drug as 
the solution to this negative experience.”48 Additionally, the authors note that the majority of 
the advertisements “associated the medication with greater social approval, often depicted by 
showing more friends, family, and recreational activities after a character obtained a 
prescription.”48 Many of the advertisements they analyzed dramatically depicted the 
medication as being a scientific breakthrough by using words and phrases such as 
“revolutionary” or “for the first time ever.”48 The last major finding in the examination of the 
2016 television advertisements was that, “the portrayal of endurance increasing as a result of 
medication use (e.g., showing a character being able to go to work, participate in family 
activities, etc.) nearly doubled in the 2016 sample.”48 The authors note that this increase 
indicates a “further broadening of claims that the medications can help with patient’s daily 
tasks and responsibilities.”48 This study reveals that even though regulation has evolved since 
2004, the commonly cited issues pertaining to the nature of the content in pharmaceutical 
commercials have persisted and even grown more extreme in recent years. Proponents of 
DTCA emphasize the educational value, but this study unfortunately indicated that over the 
years the educational value of these advertisements has declined rather than increased.  
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A study conducted by Tsai and Lancaster additionally examined the nature of DTC 
television advertisements in 2012. 44 These authors applied “Taylors six-segment message 
strategy wheel” to analyze 96 commercials that promoted a specific branded drug in order to 
gain a better understanding of the message strategies typically used by pharmaceutical 
companies in their advertisements.44 “Taylors six-segment message strategy wheel” is a tool 
that was developed in 1999 to help advertisers create effective message strategies for 
consumer-product advertising.44 This model is made up of two dimensions, characterized as the 
“ritual view,” and the “transition view.”44 Each of these views encompass three segments which 
are described in Exhibit 1 below.  










After analyzing the collection of advertisements according to this framework, the authors found 
that “for commercials that feature explicit product claims, the majority of the commercials 
adopted a combination strategy (77.2%).”44 This combination strategy involves using the ration 
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and ego approaches together. The ration approach involves providing consumers with medical 
and drug information, while the ego approach involves “appealing to the viewer's ego-related 
needs and desires (i.e., pursuing personal goals without worrying about or being hindered by a 
medical condition) through the ad narratives and imagery.”44 The authors examined the 
prevalence of each of these message strategies individually, and found that “ration-based” 
(92.4%) was the most common approach.44 They explained commercials utilizing the ration-
based approach attempted to persuade consumers by using logic and reasoning. The concluded 
that overall, “the purpose of most DTC commercials appears to be about educating consumers 
about the medical condition and the brand being advertised.”44 The “ego-based” approach was 
the second most frequently used message strategy (77.2%).44 The authors explain that “these 
campaigns stressed how taking the drug would make the viewer feel better about him/herself, 
improving their life quality, or allowing the consumers to actualize their lifestyle goals.”44 The 
other message strategies (social, routine, and acute-need) were less common, and sensory was 
the least common.44 
eDTCA 
The pharmaceutical industry’s use of the internet to distribute advertisements is 
sometimes referred to as “eDTCA,” and it is one of the fastest growing components of DTCA. In 
2015, of the $4.2 billion spent on DTCA, $1.86 billion was dedicated to online DTCA.49 This 
number increased to $2.02 billion in 2016.50 Table 3 shows the changes in spending in different 










While estimates of the current (2020) amount that the pharmaceutical industry is spending on 
eDTCA were unavailable, one can only assume that the figure has increased substantially as our 
society has undergone a massive digital transformation. Additionally, data has revealed that 
searching for health-related information has become the third most common activity for 
internet users.40 The 2005 study that included more than 6,000 adults found that “although the 
physician was still the most trusted source of information, 48.6% of the subjects went online 
first and then consulted their physician, whereas only 10.9% talked to their physician first.”40 
Another study examined the frequency with which Americans are using the internet and social 
media to disclose and receive health information and found that “over 80% of young adults 
have disclosed health information and have sought health information at least once through a 
social media channel.”49 Because the majority of Americans regularly use the internet, and 
additionally use the internet to seek health-related information, eDTCA provides the 
pharmaceutical industry with a lucrative opportunity to reach millions of potential customers.  
It is clear from a number of studies that pharmaceutical companies are increasingly 
capitalizing on this opportunity. Liang and Mackey conducted a study in 2011 to investigate the 
prevalence of eDTCA 2.0, which is online DTCA using interactive social media technology, for 
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the top 10 pharmaceutical companies. The results revealed that all 10 of the top 
pharmaceutical companies utilized eDTCA 2.0.52 Additionally, they found that “80% of the 
pharmaceutical companies also had YouTube channels and had developed health care 
communication related mobile applications.”52 The study also revealed that “for the top 10 
highest grossing drugs in 2009, 90% had dedicated websites and 80% have televised DTCA 
advertisements on YouTube and 70% have dedicated Facebook pages.”52 It is clear that 
pharmaceutical companies are increasingly incorporating social media channels such as 
Facebook, Twitter, and YouTube into their marketing strategies. In a study conducted by 
Tyrawski and DeAndrea in 2015, the researchers revealed that “all pharmaceutical companies, 
with the exception of one, had a presence on at least one social media platform.”52 This study 
also analyzed the type of advertisements that pharmaceutical companies were posting on social 
media. The researchers found that “40.7% of pharmaceutical companies posts were for help- 
seeking DTC advertisements, only 1.6% were drug product claims.”52 They also found that a 
significant proportion of consumers (23.9%) interacted with the posts by leaving comments.52 
Another study investigated how DTCA distributed through different mediums impacted the 
consumers intention to seek additional information. The study revealed that “eDTCA was 
associated with frequency to seek further information from a reliable source (i.e. a medical 
professional) whereas other forms, including newspaper and spam email were not associated 
with frequency.”52 The financial figures support these findings, indicating that eDTCA is a very 
effective sales technique with an ROI of 5:1.40 With online DTCA, pharmaceutical companies are 
able to target consumers more effectively and reach their intended audience in ways that are 
not possible with print and television ads.  
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While eDTCA does represent a significant opportunity for the pharmaceutical industry to 
increase sales by connecting with consumers on platforms that are increasingly attracting a 
growing body of users, this new avenue of advertising may present a huge challenge for policy 
makers and regulatory advisors. It appears from an analysis conducted by Hyosun Kim that it 
already has. To shed light on the emerging issue, Kim thoroughly examined “all US Food and 
Drug Administration (FDA) warning letters and notices of violations issued to drug 
manufacturers regarding their online promotional activities to consumers over the 10-year 
period spanning 2005 to 2014.”49 In total, Kim examined 73 citations, and found that “nearly 
half were in reference to a company-controlled webpage or website. A fourth of the letters 
concerned paid advertisements in the form of sponsored links or banner ads. Just two of the 
letters referred to social media messages, both of which regarded Facebook use.”49 
Additionally, she examined the nature of the complaints and found that “the common theme 
within the body of letters regarded information quality; lack of risk information and 
mischaracterized efficacy information were the most prevalent allegations, followed by 
incomplete product names and insufficient ingredient information.”49 Continued regulation of 
eDTCA is extremely important in order to ensure that the information being distributed is 
accurate and balanced, even more so, as it appears that consumers place more trust in the 
information they find online than any other form of advertisement. According to Carpentier, 
“Consumers who actively seek out online health information tend to believe the information to 
be credible, irrespective of whether a medical expert has actually authored the information.”49 
The author continues to explain that, “unlike their perceptions of other methods of DTCA, 
consumers are less skeptical of online information.” 49 Because the use of the internet and 
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social media to disseminate pharmaceutical ads is so new, the FDA is having to re-evaluate and 
update regulations. In June of 2014, the FDA released a report focusing on Twitter and issued 
requirements for pharmaceutical promotional posts on the platform. The report indicated that, 
“a company may embed a direct link within a message that directs a user to additional 
information about the product. However, in the initial message and in the linked information, 
risk information must be complete and be afforded the same prominence as benefit 
information. Furthermore, all information and links must be branded.”49 It seems as though the 
FDA will need to continue to update and add regulations as pharmaceutical companies 
continue to grow their presence on these platforms, and additionally as new platforms evolve.  
Carpentier additionally discusses the emerging issue of “un-branded” social media 
advertisements.49 Un-branded social media advertisements are user-generated posts that are 
sometimes paid for directly by pharmaceutical companies while other times they are organic. 
The author note that these types of advertisements are “particularly problematic for both 
consumers and regulators, as these messages often appear to be word-of-mouth information 
offered by a fellow layperson.”49 This article gave the example of Kim Kardashian’s paid 
endorsement on Instagram of a morning sickness drug (Diclegis). This advertisement received a 
lot of criticism and backlash, and on August 7, 2015, the FDA sent Duchesnay, Inc, the 
manufacturer of the product, a warning letter.49 The article forecasts that the pharmaceutical 
industry’s use of un-branded promotional content will increase in coming years, as consumers 
place a higher level of trust in un-branded versus branded content, and it will serve as an 
effective technique to attract users to the companies’ branded information.49 The distribution 
of un-branded pharmaceutical promotional content will require stringent regulation, as user-
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generated social media content has extreme potential to spread misinformation and encourage 
misuse. In relation to this issue, the FDA issued a draft guidance on third party misinformation 
in 2014, and stated that pharmaceutical companies will not be held responsible for user-
generated content, but the closer the company is to the creation of the advertisement, the 
greater their responsibility.49 As Americans are using the internet and social media hour-to-
hour of every day, they are consuming more pharmaceutical advertisements than ever before, 
so it is particularly important to examine the nature of these ads and the messages they are 
conveying.  
Arguments for DTCA 
 In order to develop an informed opinion on the topic of DTCA, it is important to 
understand the arguments of those individuals on both sides of the controversy. Given the fact 
that the United States and New Zealand are the only countries who allow product specific 
DTCA, one might believe that the majority of the world is opposed to DTCA, but in reality, the 
debate is quite balanced. This report will thoroughly discuss the arguments of both sides and 
present corresponding evidence that exists to validate each claim.  
 The most commonly cited argument of those in favor of DTCA is that the advertisements 
provide consumers with further education about their healthcare options and encourage them 
to take a more active role in their healthcare journey.40,53,54 Proponents claim that DTCA gives 
consumers access to a much wider variety of sources for health-information and treatment 
options, rather than having to rely solely on their health care providers. There has been no 
evidence to reveal whether health care consumers have become more informed or empowered 
since the emergence of DTCA. With that being said, it does appear that more Americans are 
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actively seeking health-related information, as data from a 2011 article revealed that searching 
for health-related information was the third most common activity among internet users.40 
Additionally, the Journal of Consumer Marketing conducted a survey of 300 patients in 2005, 
and 59% of the respondents admitted that they felt the practice of DTCA is potentially a good 
thing because it offers them empowerment.53  
 Next, DTCA proponents argue that the advertisements encourage patients to initiate 
conversations with their physicians about medical concerns. In support of this claim, a “2004 
FDA consumer survey found that exposure to DTCA prompted 27% of Americans to make an 
appointment with their doctor to talk about a condition they had not previously discussed.”40 
Ventola also noted that the majority of physicians agree with this statement, as the FDA survey 
further revealed that “53% of physicians said DTCA led to better discussion with patients and 
73% believed that consumer drug advertising helped patients ask more thoughtful questions.”40 
Other physicians hold different opinions about the effect of DTCA on their conversations with 
patients. These opinions are cited in the arguments against DTCA and will be discussed later in 
this report. 
 In relation to this argument, many claim that DTCA reduces underdiagnosis and 
undertreatment, as the advertisements increase the probability of consumers recognizing that 
they potentially have a treatable disease.40,53,54 They claim that consumers with immediate, 
direct access to health information are more likely to reach out their physicians. The evidence 
from the 2004 FDA study supported this argument, revealing that “88% of patients who had 
inquired about a medication in response to a drug ad had a condition that the drug treated.”40 
A study by Harvard University/Massachusetts General Hospital and Harris Interactive also 
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revealed evidence validating this argument. They found that “25% of patients who visited their 
doctor after seeing DTCPA received a new diagnosis; of these, 43% were considered to have a 
high-priority health condition.”40 Opponents of DTCA cite similar evidence, but feel that these 
advertisements increase overdiagnosis rather than reduce underdiagnosis. This argument will 
be subsequently in this report.  
 DTCA proponents additionally argue that DTCA reduces underdiagnosis by reducing 
stigma associated with the advertised disease.40,54 Many DTCA advertisements are for drugs 
that treat health conditions that could be embarrassing to a patient, such as depression or 
erectile dysfunction. Many claim that advertising these diseases reduces the surrounding 
stigma by raising awareness. Reducing the embarrassment associated with the disease 
increases the likelihood of consumers reaching out to their doctors and getting treatment.  
 Lastly, many individuals argue that DTCA increases patient compliance, which is the 
degree to which patients follow medical advice. According to Ventola, the “data consistently 
show that small, but statistically significant, improvements in adherence occur among patients 
exposed to DTCPA.”40 Many believe that this is because DTC advertisements act as reminders to 
patients about their medical conditions or prescriptions. Additionally, individuals claim that the 
advertisements reinforce physicians’ recommendations as patients feel more confident about 
the treatment option after they have requested their own treatment.55 A number of studies 
have supported this claim including the 2004 FDA study which revealed that “33% of physicians 
reported that DTCPA increased patient adherence.”40 Additionally, a study by Harvard 
University/Massachusetts General Hospital and Harris Interactive indicated that 46% of 
physicians felt that DTCA increased patient adherence.40 It must be noted that these studies 
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only indicated doctors’ opinions of patient adherence. There have been no conclusive studies 
on patients to reveal whether DTCA truly increases compliance. 
Arguments against DTCA 
 Over the years, a number of individuals, including the FDA and prominent medical 
societies, have become increasingly critical of the pharmaceutical industry’s DTC advertising 
tactics. The complaints particularly intensified after the DTC advertising campaigns of three 
pharmaceutical giants raised considerable ethical concern. These campaigns included “Pfizer’s 
Lipitor ads featuring Mr. Robert Jarvik, Merck & Schering-Plough’s ‘Food and Family’ ads for 
Vytorin, and Johnson & Johnson’s “cancer fatigue” ads for Procrit.”9 Pfizer’s 2008 Lipitor DTC 
advertising campaign featured a series of television commercials portraying Robert Jarvik as a 
licensed physician, when in reality he had no license to practice or prescribe medicine.48 
Additionally, in the commercials, Robert Jarvik claimed to personally take Lipitor, but 
subsequent investigation revealed that he did not take the drug until months after the 
commercials began filming.9 Merck & Schering-Plough’s “Food and Family” DTC advertising 
campaign for Vytorin involved the advertising of the product as an effective treatment for 
reducing cholesterol.9 Investigation shed light on studies that indicated the drug had no effect 
on cholesterol levels.9 Additionally, investigation revealed that the pharmaceutical 
manufacturer, Mecrk & Schering-Plough, was aware of these studies but suppressed the results 
for two years and continued their DTC marketing campaigns.9 The last controversial DTC 
campaign involved Johnson & Johnson marketing Procrit for uses that were unapproved by the 
FDA. “Procrit was approved to treat chemotherapy and dialysis-induced anemia, but Johnson &  
 76 
Johnson marketed it as a way to improve patients' quality of life.”9 Incidents like this have 
created a number of DTCA critics who claim that the sole purpose of DTCA is to drive sales and 
that the advertisements create more harm to patients than good. This report will subsequently 
discuss the negative ramifications of DTCA proposed by critics and cite the evidence supporting 
these claims.  
 One of the most common complaints about the practice of DTCA is its potential to 
confuse and misinform patients. The ability to diagnose a disease and identify the best course 
of action when treating that disease is a complex, difficult skill that doctors acquire through 
years of medical school, training, and practice. Potential issues arise when pharmaceutical 
companies encourage consumers to take on this role when there is a high likelihood that they 
lack the skills necessary to evaluate comprehensive medical information. Ventola notes that the 
content in DTC advertisements “often exceeds the eighth-grade reading level, which is typically 
recommended for information distributed to the general public.”40 While consumers may not 
fully understand the information presented in the advertisements, studies have revealed that 
they place an unwarranted amount of trust in them. One survey of patients revealed that “50% 
of respondents thought that the ads were approved by the government, 43% thought that a 
medication had to be completely safe for it to be advertised; and 22% thought that a drug 
known to have serious side effects could not be advertised.”40 With all of this being said, it is 
particularly concerning that many of the advertisements omit important information. One 
study revealed that, “82% of DTCPA ads made some factual claims and rational arguments for 
use of the advertised drug; however, only 26% of the ads described risk factors or causes of the 
condition, and only 25% mentioned prevalence.”40 Additional studies have revealed that 
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doctors agree that DTCA is not as educational as it should be and can cause misunderstanding 
among patients. According to an FDA survey, “75 percent of physicians surveyed believe that 
DTC ads cause patients to think that [a] drug is more effective than it truly is.”9 The FDA survey 
also revealed that while “53% of physicians said DTC ads lead to "[b]etter discussion[s] with 
patients,” only 10% of those physicians believe that the advertisements had an educational or 
informational component for patients.9 The authors of a ScienceDirect article discussed a report 
published by Aiken and colleagues that asked doctors about patients’ understanding of 
medicines presented in DTC advertisements.52 The report revealed that “whilst 78% stated that 
they believed that the patient understood the benefits of the medication, only 40% believed 
that patients understood the risks and potential problems with the medications. Furthermore, 
30% believed that patients understood drug efficacy information and 25% understood the type 
of people who should avoid this drug.”52  
The fact that many DTC advertisements overemphasize benefits and minimize risk is a 
commonly cited argument against DTCA. From 1997 to 2006, nearly 84% of the regulatory 
letters for DTCPA cited ads for either minimizing risks (e.g., omitting information about side 
effects) or exaggerating a drug’s effectiveness (e.g., portraying the indication too broadly or 
making unsubstantiated claims of superiority over other drugs), or both.”40 The risk portion the 
advertisements are often overlooked or ignored by consumers because they are generally 
displayed in very small print or recited very quickly at the end of a television commercial. 
Additionally, many advertisements make use of pleasant visual imagery while the narrator lists 
the serious side effects. According to Ventola, “research has shown that when visual and verbal 
messages are discordant, visual messages tend to predominate, which can result in insufficient 
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processing of verbally presented risk information.”40 Patients themselves have expressed 
concern about the lack of information about risks presented in the commercials. Friedman and 
Gould conducted a survey of 300 patients in 2005 to assess consumers perceptions of DTCA, 
and 46% of respondents agreed strongly that advertisements do not give enough information 
about the possible risks and negative side effects of using the drug and 23% agreed 
somewhat.53 Evidence has shown that the majority of consumers don’t have the expertise 
necessary to comprehensively evaluate the medical information presented in DTC 
advertisements, especially when deceptive techniques are used to minimize risk information. 
Encouraging consumers to take on this role and use the presented information to make their 
own health-care decisions causes a number of potential issues. 
One of these potential issues is that DTCA puts strain on the doctor-patient relationship. 
When patients go into their doctors’ offices and request a specific medication after seeing a 
DTC advertisement, it puts the physicians in an uncomfortable situation where they have to 
balance their desire to satisfy their patient with their obligation to uphold their expert medical 
opinion. According to a national survey cited by Ventola, “39% of physicians and 30% of 
patients felt that DTCPA interfered with the physician–patient relationship.”40 This negative 
impact has been well-documented. Ventola explains that “denial of a prescription request has 
been shown to decrease patient satisfaction and increase physician switching.”40 To support 
this claim, he cites a study that revealed that, “nearly half of the patients reported feeling 
disappointed about not receiving a requested medication. One-quarter of the patients said they 
would try to change their physician’s mind or get the drug elsewhere, and 15% said they were 
considering switching physicians.”40 Many studies have revealed that doctors find it very 
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frustrating and challenging to convince patients of their medical opinion that contradicts with 
“evidence” the patients bring in from a DTC advertisement.40 Because of these reasons, many 
doctors feel pressured to prescribe drugs requested on the basis of DTC advertisements. 
According to an FDA survey, “eight percent of physicians felt very pressured and 20 percent felt 
somewhat pressured to prescribe the specific brand name drug when the patient asked the 
physician to do so.”45  
When physicians feel pressured to prescribe medication requested by their patients, it 
may lead to inappropriate prescribing. This is another commonly cited argument of DTCA 
opponents. The authors of a BMJ article discussed a study that examined the impact of DTCA in 
the US compared with Canada by surveying patients and physicians.46 The results revealed that, 
“patients in the US were more likely to request DTCA drugs, and physicians in both settings 
were more likely to acquiesce to these requests despite feeling ambivalent about the drug that 
was prescribed.”46 Additionally, “those who requested a specific DTCA drug were 16 times more 
likely to receive a drug than those who did not request a specific drug.”46 While this study did 
not address whether the prescriptions written were appropriate treatment options for 
particular patients’ illnesses, it is clear that patient requests for DTCA drugs have the ability to 
encourage physicians to write prescriptions, in spite of potential uncertainty. Additionally, 
critics believe that DTCA can cause inappropriate prescribing because it may encourage 
consumers to “withhold information to fit a particular profile that they saw in DTC ads in an 
attempt to get the doctor to prescribe a drug they want but that might not be appropriate for 
them.”40 Only doctors have the knowledge and experience to make the difficult decision 
regarding diagnosis and treatment, and it is important that consumers continue to trust their 
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physicians to make the ultimate judgment, regardless of the information they find in 
pharmaceutical advertisements.  
The next widely discussed complaint about the practice of DTCA has to do with the 
timing of DTCA campaigns which this report previously discussed in the section on timing and 
trends. As mentioned earlier, the majority of DTC advertisements are published or aired within 
a year after FDA approval. According to Ventola, “clinical trials required for FDA approval are 
typically not designed to detect rare adverse effects, and current methods of postmarketing 
surveillance often fail to connect adverse events that have a high rate of background 
prevalence with the use of a particular drug.”40 Thus, the safety profile of a majority of the 
drugs being advertised is not fully known. One of the most commonly cited examples pertaining 
to this issue is the recall of Vioxx in 2004. From 1999 to 2004, Vioxx was one of the most heavily 
promoted pharmaceuticals, and during that time, the product manufacturer, Merck, spent over 
$100 million per year on marketing. Vioxx was used to treat osteoarthritis and widely 
prescribed among physicians.9 An internal study conducted by Merck revealed that patients 
who took Vioxx had a five times increased risk of heart attack.9 After withholding the data for 
years and sacrificing the lives of patients for profit, Merck voluntarily withdrew the product 
from the market on September 30, 2004.9 The case of Vioxx is not unique. According to 
Ventola, “Other drugs that were heavily promoted to consumers have also been linked to 
safety advisories, FDA black-box warnings, and withdrawals from the market. These include 
benoxaprofen (Oraflex, Eli Lilly) for arthritis, troglitazone (Rezulin, Parke-Davis) for diabetes, 
cisapride (Propulsid, Janssen) for gastric reflux, cerivastatin (Baycol, Bayer) for high cholesterol, 
and tegaserod (Zelnorm, Novartis) for irritable bowel syndrome in women.”40 As this report 
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mentions previously, a number of parties within the medical community have come forward 
and called for regulation of the pharmaceutical industry’s ability to market their products 
before their full safety profiles are known. Yet, no significant action has been taken to delay 
advertising for new products.  
Additionally, a large amount of literature has discussed the “me-too” drug 
phenomenon. Critics argue that the pharmaceutical industry uses DTCA to promote expensive 
“copy-cat” drugs that might not offer any significant benefit over older, cheaper medication.40 
Connors notes that there is no universal definition of disease, and because of this, 
“manufacturers are free to ‘sell expensive drugs with marginal benefits over older’ and cheaper 
versions.”9 These drugs have been called “me-too” drugs. According to The Truth about Drug 
Companies from 1998 to 2002, “415 new drugs were approved by the Food and Drug 
Administration (FDA), of which only 14 percent were truly innovative. A further 9 percent were 
old drugs that had been changed in some way that made them, in the FDA’s view, significant 
improvements.”4 Angell continues to explain that the remaining 77% were all me-too drugs, 
that were classified by the FDA “as being no better than drugs already on the market to treat 
the same condition.”4 Some of these me-too drugs had slightly different chemical compositions 
but the majority of them did not. The author explains that the manufacturing of these type of 
drugs is made possible by the fact that the FDA only requires that pharmaceutical companies 
show that the new drugs are “effective,” not “more effective” than other existed drugs being 
used to treat the same condition.4 Ventola gives specific examples of the promotion of 
expensive “me-too” drugs, explaining that “two heavily promoted diabetes treatments, 
rosiglitazone (Avandia, GlaxoSmithKline) and pioglitazone (Actos, Takeda), were found to be no 
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more effective—or safe—than older drugs, even though they were much more expensive.”40 
Because the process of bringing a completely new drug to market is so costly and time-
consuming and the probability of successfully developing a new drug is so rare, many 
pharmaceutical companies turn to “me-too” drugs to grow their profits.  
The last major argument used in the case against DTCA is the idea that the 
pharmaceutical industry is using these advertisements to “manufacture diseases.” Some refer 
to this practice as “disease mongering” and define it as the “phenomenon wherein drug 
developers create a new disease state as part of a carefully planned marketing campaign to sell 
their latest drug of choice.”52 In less extreme terms, many claim that the pharmaceutical 
industry uses DTCA to “reframe and medicalize human traits to create a need for the drug.”26 
Before seeing these advertisements, patients may view their conditions a natural, trivial 
ailments that are inherent to the human condition. Pharmaceutical companies market these 
commonly experienced ailments as “conditions” or “diseases” that can be treated with their 
products in order to create markets which did not previously exist and drive demand. Connors 
additionally discusses this issue, and refers to this tactic as the targeting of “lifestyle diseases” 
in order to “widen their productivity net.”9 A large volume of literature exists on this issue, and 
a number of authors cite a variety of examples of the pharmaceutical practice of “disease 
manufacturing.” Both Connors and Ventola use the example of erectile dysfunction (ED) drugs 
which target men who may experience normal variations in sexual performance.9,40 According 
to both of these authors, “only 10% of American men experience total inability to achieve an 
erection.”40 Therefore, many of the men who take ED drugs may actually be experiencing 
“normal” issues, but are using the drug to treat a “socially-constructed” disease. Connors also 
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notes that the more anxiety pharmaceutical companies can create in their advertisements of 
ED, the larger the market, as worrying about ED may in fact cause ED.9 In this discussion, 
Connors also used the advertisement of Paxil as an example of the pharmaceutical company 
GlaxoSmithKline (GSK) marketing a “lifestyle disease.”9 Paxil was an antidepressant used to 
treat social phobia, a disease that affected only a small percent of the population. Connors 
explains that, “GSK extended the definition of social phobia to include ‘shyness’ and played 
upon people's fears in order to enlarge its market. Only a month after 9/11, GSK aired ‘an 
advertisement of a woman walking on a crowded street, her face strained, in a crowd 
otherwise blurred. The caption read '[m]illions suffer from chronic anxiety. Millions could be 
helped.’”9 The author discusses the notion that this advertisement took advantage of the fear 
felt by the entire US population after the 9/11 attacks, and tried to convince consumers that 
this fear and additionally their potential shyness could be treated with Paxil. Authors list a 
number of other drugs that have been marketed to treat natural or trivial conditions such as 
bladder medication (Detrol), baldness medication (Rogaine and Propecia), low testosterone 
medication, and more.9,26,40,46 Many feel that the practice of “disease manufacturing” 
exacerbates unhappiness about normal experiences and has created an over-medicated 
society. From 2000 to 2012, the proportion of Americans taking five or more medications nearly 
doubled, jumping from 8.2% to 15%.57 The United States holds the position of the most 
medicated country in the world, but whether this is caused by the practice of disease 
manufacturing remains unclear. Additionally, many feel that the development of drugs to treat 
natural, trivial conditions is time wasted not spent on developing drugs to treat more serious, 
life-threatening conditions.  
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A Call for More Stringent Regulation 
Given all of the previously discussed negative ramifications of DTCA, a number of 
individuals have called for increased regulation of the pharmaceutical marketing practice. 
Despite the growing number of complaints, the FDA has done little to heighten the 
requirements for DTCA. Not only do people feel that there is not enough regulation in place, 
but they also feel that the FDA is doing an insufficient job of enforcing the current regulation. 
As mentioned previously in this report, pharmaceutical companies must submit their 
advertisements to the agency before airing or publishing, but they do not have to obtain official 
approval before doing so. If the FDA finds that a DTC pharmaceutical advertisement violates the 
rules set forth, they respond by issuing violation letters, which are no more than a warning. This 
regulatory process is supposed to protect consumers and hold drug companies accountable for 
the information they distribute. But are they really being held accountable? As the number of 
DTC advertisements has increased exponentially in recent years, one would logically expect that 
the number of violation letters would increase as well. But this isn’t the case. From 1997 to 
2016, number of DTC advertisements increased from 79,000 to 4.6 million ads while the 
number of letters of violation issued fell from 142 to 11.56 Figure 10, taken from Medical 






Figure 10. FDA Prescription Drug Advertising Violation Letters and Promotional 









A study from The New England Journal of Medicine examined these violation letters 
from 1997 to 2006.47 During this period, they found that the proportion of violation letters 
citing problems with Direct to Consumer Advertisements increased from 15.5% to 33.3%.47 
Additionally, they revealed that “nearly 84% of regulatory letters regarding direct-to-consumer 
advertising cited advertisements for either minimizing risks (e.g., minimizing or omitting 
information on side effects), exaggerating effectiveness (e.g., portraying the indication too 
broadly or making unsubstantiated claims of superiority over other drugs), or both.”47  
One argument might be that pharmaceutical industry compliance with regulations has 
increased over the years, but many believe that the enormous overflow of DTC advertisements 
has led to worsening FDA oversight. The authors of The New England Journal of Medicine article 
discuss possible reasons for the weakening of advertising regulations. They note that “in 2002 
the Secretary of Health and Human Services began requiring that all draft FDA regulatory 
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letters, including letters related to advertising violations, be reviewed and approved by the 
FDA's Office of Chief Counsel before they are issued.”47 A report prepared by the U.S. 
Government Accountability office revealed that “this legal review has led to a reduction in the 
number of letters issued, as well as to delays such that FDA warning letters are frequently sent 
out long after the false or misleading advertising campaign has run its course.”47 These authors 
additionally note that the number of FDA officials responsible for reviewing DTCA has remained 
stable over the years as the number of advertisements have grown exponentially and speculate 
that a shortage of staff may be contributing to worsening oversight.47 Lastly the authors note 
that “the proportion of broadcast advertisements that underwent FDA review before airing 
declined from 64% in 1999 to only 32% in 2004.”47 They argue that this evidence supports their 
hypothesis that staffing has not kept pace with the growing number of advertisements, leading 
to a decrease in review.  
 Regardless of the arguments for or against DTCA, advertisements for prescription 
medication have the potential to impact the consumers health and well-being and should be 
carefully reviewed and strictly regulated. The numbers are clear—regulatory action taken by 
the FDA regarding pharmaceutical marketing of prescription drugs has dramatically declined in 
recent years. This is particularly concerning when considering the evidence presented in 
numerous studies that indicates DTCA advertisements are continuing to present confusing and 
misleading information and minimize risks. The growing number of advertisements should not 
present an excuse for more laxed regulation, but rather a need more heightened oversight than 
ever before.  
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Part IV: DTPP and DTCA 
 While multiple studies have examined the impact of DTPP and DTCA individually, fewer 
studies have examined the impact of using both DTPP and DTCA together to market a 
pharmaceutical product. It appears that DTPP in itself is more effective in driving prescription 
sales than DTCA, but employing DTCA in combination with DTPP can further drive sales. In a 
2014 article from the National Bureau of Economic Research, Datta and Dave discuss a study 
that examined interactions between marketing elements.17 The study was conducted by 
Narayanan, Desiraju, and Chintagunta who utilized monthly data on three branded second 
generation anti-histamines from 1993-2002.17 The researchers found that “detailing primarily 
and positively affects brand share, whereas DTCA has a significant positive effect on both brand 
shares and class sales.”17 They also found that DTPP generates a much larger ROI than DTCA, 
and explained that this was most likely due to the fact that DTPP is much more targeted. This 
study also revealed “synergy” between the two marketing tactics. Datta and Dave note that “a 
sales call to a physician’s office has a higher marginal impact on brand share when combined 
with DTCA.”17 After a comprehensive literature search, I was unable to find additional studies 
that examined the impact of combining DTPP and DTCA for a particular pharmaceutical 
product, but it seems reasonable to postulate that utilizing these two individually powerful 
techniques together would be effective. DTCA encourages consumers to see their doctors and 
request the advertised medication, and DTPP employs detailing, sampling, and other tactics to 
encourage and incentivize physicians to acquiesce to those patient requests. The 
pharmaceutical industry has discovered how to effectively advertise to all of the parties 
involved in the sale of prescription medication, both on the demand and the supply side.  
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Conclusion 
 While pharmaceutical companies are in the business of developing life-saving drugs, 
they are also in the business of making money. The market for pharmaceuticals is worth over a 
trillion dollars. The massive success of the pharmaceutical industry cannot be simply attributed 
to the inherent demand for their products. Through marketing, the pharmaceutical industry has 
conditioned both physicians and patients to believe that their products are the answer to any 
and all ailments. America has become the most medicated country in the world, and while 
there are likely a number of different reasons for this, pharmaceutical marketing plays a major 
role.  
 This report describes in detail the marketing activities used by pharmaceutical 
companies to target both physicians and consumers directly. The most influential DTPP 
activities appear to be detailing, sampling, and “educational” activities. All of these promotional 
efforts share the underlying aim of creating favorable, reciprocal relationships between the 
industry and physicians. DTCA appears to be primarily distributed through television and 
increasingly online. Consumer targeted ads have proven to be highly effective in encouraging 
viewers (and readers) to request the advertised medication from their doctors. All of these 
activities, both individually and in combination, appear to have a significant influence on both 
physician and consumer behavior and result in a considerable increase in prescription sales. The 
pharmaceutical industry asserts that DTPP and DTCA create a number of benefits for both 
physicians and patients, but over the years, doctors, patients, and organizations within the 
medical community have grown increasingly concerned about the ethicality of industry 
influence. This report describes both the positive and negative impacts of pharmaceutical 
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promotion, but after conducting a comprehensive analysis of literature on the subject, the 
present nature of the practice may be creating more harm than good.   
While there are many issues with the current practice of pharmaceutical marketing, it 
should not be considered as “evil.” Pharmaceutical marketing has a number of positive impacts. 
Physicians and patients benefit from increased access to information about health conditions 
and treatment options. However, given the evidence presented in the large volume of literature 
written on the negative ramifications of pharmaceutical marketing, it is clear that the current 
nature of the practice is flawed. It is May of the year 2020, and we are living in unprecedented 
times. Our world is in the midst of a pandemic as the coronavirus outbreak began just four 
months ago. As of April 21, 2020, 2.5 million people throughout the world have been diagnosed 
with a never-before-seen virus, and 171,718 of those people have lost their lives.59 The health 
of not only our nation, but the world has never been more at risk and in need of life-saving 
pharmaceutical efforts. Now, more than ever there is a need to reevaluate the business 
practices of the pharmaceutical industry. It is not necessary for doctors to be flown to Hawaii to 
learn about the latest advances in medicine, and patient’s do not need to be distracted with 
charming visuals while listening to serious risk information associated with their potential 
treatment option. The world is in need of life-saving medication and education about treatment 
options stripped of the biased frills interwoven into pharmaceutical promotional content. 
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